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ABSTRACT  
   
Background.  Research suggests that non-O blood types are at an increased risk 
of thrombosis and related health complications in cardiovascular disease (CVD).  
This is due in part to higher concentrations of von Willebrand factor (VWF), an 
important factor involved in blood clotting. 
Objective.  The purpose of this study was to examine the effects of a vegetarian-
like diet on blood coagulation and other health parameters in adults with type A 
blood compared to type O blood over a four week intervention.  Given the lack of 
previous research on blood type and diet, it was hypothesized that no difference in 
blood coagulation would be observed. 
Design.  This study was a randomized, parallel arm, dietary intervention using 
healthy, omnivorous adults with blood types A and O.  A total of 39 subjects 
completed the study.  Subjects were randomized into two groups: a vegetarian-
like diet group made up of 12 type As and 12 type Os and an omnivorous control 
diet group made up of 11 type As and 12 type Os. At weeks 0 and 4, fasting blood 
was drawn and analyzed for prothrombin time (PT), activated partial 
thromboplastin time (APTT), von Willebrand factor (VWF), total cholesterol, 
LDL, HDL, triglycerides, and CRP.  In addition, subjects were weighed and filled 
out a FFQ at weeks 0 and 4. 
Results.  After adhering to a vegetarian-like diet for four weeks, type Os had a 
significant increase in PT (+0.24±0.32 sec/ p=0.050), whereas type As saw no 
significant change.  There was a trend of weight loss for type Os in the 
vegetarian-like diet group (-1.8±2.6 lb/ p=0.092) and significant weight loss for 
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type As (-0.9±2.1 lb/ p=0.037).  Both blood types O and A experienced 
significant decreases in BMI (-0.3±0.4/ p=0.092 and -0.2±0.3/ p=0.037, 
respectively).  No change was seen in APTT, VWF, total cholesterol, LDL, HDL, 
triglycerides, or CRP. 
Conclusion.  Type Os saw an increase in PT, perhaps indicating a reduction in 
risk of thrombosis and its related health complications.  Type As were less 
responsive to the dietary intervention and may require more rigid dietary 
guidelines or a longer time on such a diet to see the benefits. 
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Chapter 1 
INTRODUCTION 
Overview 
More than 5 million copies of the diet book “Eat Right 4 Your Type” by 
naturopathic doctor Peter J. D’Adamo have been sold in over 50 languages since 
its publication in 1996 (1).  In the book, D’Adamo purports that lectins in food 
interact with blood antigens and affect the state of health of the individual.  He 
asserts that by eating a specific diet that excludes food sources of lectins that 
interact poorly with one’s blood type, an individual will experience health 
benefits including weight loss, reduced disease risk, and even improved emotional 
outlook (2).  Given the book’s popularity among individuals seeking alternative 
dietary advice, scientific validation of these recommendations should be sought.  
D’Adamo has been criticized by the scientific community for his lack of scientific 
evidence to support his claims and his book has been labeled “pseudoscience” (3). 
Although D’Adamo does not offer scientific support for his diet claims, 
there is some evidence that ABO blood types differ in their disease risk.  Non-O 
blood types may be at increased risk for development of coronary atherosclerosis 
and increased risk for mortality during ischemic heart disease (4).  Non-O blood 
type has also been associated with an increased risk for pulmonary embolism (5).   
Thrombotic occlusion is often the cause of both myocardial infarction and 
embolism.  Increased levels of a particular clotting factor in plasma, the von 
Willebrand factor (VWF), has been associated with an increased risk of arterial 
thrombosis, including myocardial infarction and stroke (6).  Interestingly, VWF 
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concentrations are higher in the plasma of non-O blood types compared to the O 
blood type; a consequence of A and B antigen expression on VWF and the 
slowing of its clearance due to the presence of those antigens (6, 7).  Given the 
higher levels of VWF in non-O blood types, perhaps there is an opportunity for 
personalized nutrition, e.g. a “blood type diet” for A blood type individuals to 
lower the risk of thrombosis. 
A variety of studies have been conducted to assess the effect of dietary 
intervention on hemostasis, however, no such study has been conducted using 
D’Adamo’s blood type diet.  D’Adamo suggests that individuals with type A 
blood do best on a vegetarian-like diet that emphasizes soy proteins, grains, fruits 
and vegetables, with the allowance of some fish and poultry (2).  A literature 
review identified a number of studies on plant-based foods, including soy, garlic, 
and purple grapes, which have demonstrated antithrombotic effects (8).  Although 
D’Adamo never mentions VWF in his book, this may be a missing link that 
supports the reasoning for the type A diet.  Given that non-O blood types have 
higher levels of VWF and that some plant-based foods have been shown to have 
antithrombic effects, perhaps the type A diet will lower the risk for blood clotting 
among type A individuals. 
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Statement of Purpose 
The purpose of this study is to examine the effects of the type A, 
vegetarian-like diet on blood coagulation and other health parameters in adults 
with type A blood compared to type O blood over a four week intervention, and 
also compare the experimental group with a control group composed of both type 
A and O blood groups that receive no dietary intervention. 
Hypothesis 
 Given the lack of previous research in the area of blood type diet, it is 
hypothesized that no difference in blood coagulation will be observed between 
type A and O blood groups after adhering to the type A, vegetarian-like diet for 
four weeks.   
Definition of Terms 
Antibody: a protein created by the immune system that is capable of binding to 
antigens and eliciting an immune response 
Antigen: a substance foreign to the body that evokes a response from the immune 
system and is capable of binding antibodies 
Embolism: the sudden obstruction of a blood vessel by an abnormal particle 
referred to as an embolus 
Hemostasis: the process of arresting blood flow, as in blood coagulation 
Thrombosis: the presence or formation of a blood clot inside a blood vessel 
Lectin:  a protein, usually derived from plants, that is not an antibody and is not 
created by the immune system, but binds carbohydrate receptors on cell surfaces 
(for example, those found on the surface of RBCs) 
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All definitions were compiled from the National Institute of Health’s MedlinePlus 
(9).  
Delimitations and Limitations 
 The majority of study subjects are adult male and female college students.  
Therefore the findings of the study are only generalizable to this population.  
Also, only type A and O blood types were included, so the results do not apply to 
other blood types (B and AB).  
 Limitations of this study include the reliance on subject compliance to 
adhere to the vegetarian-like diet and limited control over the amounts and ratios 
of allowed foods consumed. 
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Chapter 2 
REVIEW OF LITERATURE 
ABO Blood Type 
Discovery 
Until the discovery of the ABO blood groups, blood transfusions between 
humans were intermittent in their success, often resulting in the death of the 
patient.  For this reason, they were outlawed in some countries (10).  Austrian 
born scientist, Karl Landsteiner, addressed this problem in his laboratory at the 
turn of the 19
th
 century by conducting experiments in which he mixed blood from 
two different individuals.  With some combinations he observed the red blood 
cells (RBCs) forming clots, whereas other mixtures showed no effect at all.  It 
became clear that blood should not be transfused from a donor to a recipient that 
resulted in the agglutination of RBCs.  Landsteiner deduced that each individual’s 
serum contained antibodies that caused the agglutination of the RBCs of other 
non-compatible individuals by targeting antigens on the surface of their RBCs.  
However, an individual’s serum did not contain antibodies for the antigens 
present on his own RBCs.  This basic rule of immunology, known as the 
“Landsteiner’s Rule,” was first described by Landsteiner in his paper 
“Agglutination phenomena of normal human blood” published in the Viennese 
Weekly Journal of Medicine in November 1901 (11).  Twenty-nine years later he 
was awarded the Nobel Prize for this landmark discovery (10).   
Landsteiner originally identified three blood groups, and a fourth was 
described a year later by Decastello and Sturli in a study published in 1902 (12).  
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At first, the four blood types were known as I, II, III and IV.  Later, scientists 
Ludwik Hirszfeld and Emil von Dungern renamed the groups as A, B, AB and O 
(13).  The letter assigned to the blood type corresponds to the antigen present on 
the surface of the RBC.  For example, type A has the A antigen, type B has the B 
antigen, and type AB has both.  Type O signifies the absence of A and B antigen 
and was named after the German word ‘ohne’ meaning ‘without’ (14).  According 
to Landsteiner’s Rule, an individual’s serum does not contain antibodies that 
target its own RBC antigen, but it does have antibodies against all foreign 
antigens.  For example, type A serum has B antibody, type B serum has A 
antibody, and type AB serum does not contain either antibodies.  Type O, on the 
other hand, contains both A and B antibodies (see Figure 1). 
 
Figure 1. ABO blood group antigens and antibodies 
Discovery of the ABO blood types allowed for blood transfusion to 
become a safe medical practice and saved many lives in the face of excessive 
blood loss.  As knowledge of the ABO blood types expanded, many subcategories 
were identified based on variation in the expression of A and B antigen.  For 
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example, in some type A individuals, the expression of the A antigen is 
weakened.  Subcategories of the A blood group were established over time based 
on their reactivity to antibodies and the presence of antigen in secretory products, 
such a saliva.  Weaker forms of the B antigen have also been identified, however 
to a lesser extent than A antigen subgroups.  Different phenotypic subgroups are 
depicted using a subscript number or letter.  The most common ABO phenotypes 
are A1, A2, B, A1B, A2B, and O (14, 15).   
Inheritance 
In 1910, Hirszfeld and von Dungern determined that blood type is 
inherited according to Mendelian laws, following a codominant autosomal design 
(13, 14).  This means that one allele for the gene that determines blood type 
(located on a non-sex chromosome) is inherited from each parent, giving the 
offspring two alleles of the gene.  These alleles are codominant, meaning they are 
expressed equally.  For example, if a child inherits the allele for type A blood 
from his mother and the allele for type B blood from his father, the child will 
express both alleles and have both A and B antigens present on their RBCs.  
However, if the child receives a type B allele from his father and a type O allele 
from his mother, the child will be blood type B, because only the B antigen will 
be expressed on the RBCs (recall that type O represents the absence of antigens).  
A simple Punnett square illustrates the possible genotype inheritance of an 
offspring based upon the alleles possessed by the parents (see Figure 2).  
Interestingly, the inheritance of ABO blood type was one of the first human 
genetic markers used in forensic science and paternity testing (16).  
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 Father 
Mother A B O 
A AA AB AO 
B AB BB BO 
O AO BO OO 
Figure 2. ABO genotype in offspring 
Biochemistry 
The ABO antigens are sugars that project from the surface of RBCs.  The 
sugar molecule L-fucose serves as a building block upon which the ABO antigen 
is attached.  In type O individuals, no additional sugars are attached to fucose.  
This precursor substance is often referred to with the letter ‘H’.  In type A and 
type B individuals, a glycosyltransferase enzyme is responsible for adding the 
final oligosaccharide to the H antigen to form A or B antigens.  The addition of 
N-acetyl-D-galactosamine results in the A antigen whereas the addition of D-
galactose results in the B antigen.  As discussed previously, some individuals 
present both A and B antigens (14).  Beyond red blood cells, these antigens are 
also expressed in other various tissues including vascular endothelium, epithelial 
cells, and platelets.  For this reason, some researchers suggest that they be called 
ABO “histo-blood group” antigens (17). 
Molecular Genetics 
In the modern age of genomics, much information has been revealed about 
the complexities of ABO blood type genetics.  What once was a seemingly simple 
blood grouping system has revealed itself to be rather complex.  Perhaps contrary 
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to what would be expected, the antigens on the RBCs are not coded by genes 
directly.  Instead, the ABO gene codes for enzymes (glycosyltransferases) that 
produce the oligosaccharide epitopes (the part of the antigen recognized by the 
immune system).  Specifically, the A antigen is made by 3-α-N-
acetylgalactosaminyltransferase (A transferase) and the B antigen is made by 3-α-
N-galactosaminyltransferase (B transferase), both of which are coded from a 
single ABO gene located on the long arm of chromosome 9 (9q34) (14, 15).  The 
main alleles of the ABO gene were first defined by Yamamoto and his colleagues 
in 1990 (18).  They found that the allele that codes for A transferase versus B 
transferase is different by only 7 out of 1062 nucleotides, which results in a 
difference of only four amino acids substitutions.  Blood type O was found to be 
the result of the deletion of a single guanosine nucleotide that shifts the reading 
frame of the gene, and results in the translation of a shortened protein which has 
no glycosyltransferase functionality.   
Since the work of Yamamoto in 1990, new alleles of the ABO gene are 
continuously being identified.  Allelic variants impact the specificity and efficacy 
of the resultant glycosyltransferases, and therefore produce the various phenotypic 
subtypes identified earlier in this paper.  For example, a SNP (single nucleotide 
polymorphism) in the gene can result in a decreased capacity for the 
corresponding transferase enzyme to function normally (15).  If the affinity of the 
enzyme for its substrate is lessened, the result would be a weaker phenotype, in 
which less of the corresponding RBC antigen is expressed.  Numerous missense 
and nonsense mutations result in various alleles that ultimately alter the 
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phenotype of an individual.  New alleles of the ABO gene will likely continue to 
be discovered, but as of April 2009, Storry and Olsson identified 181 alleles (65 A 
alleles, 47 B alleles, 58 O alleles, and 11 AB alleles) (14).   
Evolution and Anthropology 
 It appears that ABO blood group antigens served an important function 
over the course of human evolution, because the frequency of blood types varies 
among different populations.  It has been speculated that having a certain blood 
type over another conferred some sort of selection advantage, such as resistance 
to infection.  Blood type O is the most common phenotype in all races, 
comprising 44% of Caucasians, 49% of Blacks, and 43% of Asians.  Native 
American Indians are almost exclusively type O.  Blood type A is the second 
most common, with its collective phenotype comprising 43% of Caucasians, 27% 
Blacks, and 27% of Asians.  Type A is abundant in Northern and Central Europe, 
but is rarer in Asia.  Blood type B appears in 9% of Caucasians, 20% of Blacks, 
and 25% of Asians.  Type B is popular in Central Asia, but nearly absent in 
Amerindians.  Finally, type AB is the rarest phenotype in all races, making up 
only 4% of Caucasians, 4% of Blacks, and 5% of Asians (14, 19). 
 The reason for the varied distribution of blood type among different 
populations is not well understood, and several theories about its evolution have 
been espoused since the discovery of ABO blood groups over 100 years ago.  The 
current evolutionary theory has been developed from in depth statistical analysis 
of the numerous SNPs occurring at the ABO gene locus.  In their 2008 study, 
Calafell et al. speculated that the oldest human DNA sequence coded for the type 
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A phenotype.  Based on their calculations, type B phenotype appeared next 
approximately 3.5 million years ago.  After that, the allele which coded for type O 
blood appeared around 2.5 million years ago.  Over time, various mutations in the 
ABO gene gave rise to the different subtypes of the A, B, and O phenotypes that 
have been mentioned previously.  Calafell’s study also supported earlier 
speculation that interactions with pathogens in different geographical regions 
likely caused certain mutations to be selected over time because they conferred 
some advantage to their host (20).  
Blood Group Typing 
 Blood group typing is the process that determines which antigens (A 
and/or B) are present on the red blood cells of an individual.  It should be noted 
that the D antigen (also known as Rh) is usually tested for as well, but is not 
relevant to the context of this paper.  Blood group typing is used in blood 
donation, blood transfusions, and organ transplantation to assure that the donated 
blood/tissue is compatible with the receiver.  Typically, a sera containing 
antibodies for the ABO antigens is used to identify blood type.  However, the 
reverse logic can be applied, in which ABO antigens are used to spot expected 
antibodies in serum – a process called reverse ABO grouping (21).   
 A number of blood group typing tests exist, most of which use the 
agglutination of red blood cells as a positive indication of antibody and antigen 
interaction.  One of the oldest is the slide test method, in which a drop of 
antiserum is mixed with blood on a stone or glass slide.  If an agglutination 
reaction is observed, it means that the antibody present in the antisera reacted with 
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the antigen on the red blood cells, causing them to clump together.  For example, 
a drop of anti-A that causes agglutination of the blood would reveal that the blood 
tested is type A.  The main advantages of the slide test method are that it is quick 
and inexpensive.  It also does not require the use of a centrifuge, as do some other 
tests.  However, it is not as sensitive as other tests now available, including the 
tube test, microplate method, and gel centrifugation assay.  Nowadays, advanced 
technology allows for molecular blood group typing, which involves the 
genotyping of DNA and detection of SNPs to diagnose blood type (21).   At-home 
kits have also been created so that individuals can easily determine their blood 
type using a whole blood sample from a simple finger prick.  The kits come with 
a test card that is divided into separate areas that have been treated and 
impregnated with dried antiserum (anti-A, anti-B, and anti-D/Rh).  A small drop 
of blood is gently rubbed over each antiserum site.  A positive reaction of 
agglutination indicates that the corresponding antigen is present on the red blood 
cells (see Figure 3) (22).    
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Figure 3. Sample blood typing kit
a
 
aImage courtesy of Craig Medical Distribution Inc., Vista, CA. 
ABO and Disease 
 When a patient receives an incompatible blood transfusion, it causes 
hemagglutination and can potentially result in death.  This situation is due to 
medical intervention; however, a similar situation can occur naturally during 
pregnancy.  Hemolytic Disease of the Newborn (HDN) takes place when the fetus 
and mother have different blood types.  The mother’s serum antibodies can attack 
the red blood cells of the fetus and cause symptoms of anemia, edema, and 
jaundice in the newborn baby.  Typically symptoms are mild and do not require 
medical intervention, however in some cases they are severe and result in death 
(3, 23). 
 ABO blood type has also been associated with infectious disease.  As 
discussed earlier, the evolution of blood type was likely influenced by pathogens.  
Pathogens often use the host’s cell surface receptors, such as the sugar-based 
ABO antigens, for attachment.  Certain ABO antigens interact with pathogenic 
invaders more easily than others.  For example, blood type O has been found to 
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have a greater susceptibility to peptic ulcer caused by Helicobacter pylori because 
the bacteria has a greater affinity for the H antigen compared to the A and B 
antigens (24).  On the other hand, there is strong epidemiological evidence that 
blood group O provides protection against Plasmodium falciparum malaria, 
whereas blood group A has been associated with more severe malaria.  During 
infection, type O blood is less prone to form rosettes (aggregates of malaria 
infected erythrocytes with uninfected cells) (25).  Surface antigens mediate the 
adhesion of pathogens and thus affect the progression and severity of infection.  
 Some forms of cancer are linked to blood type.  For example, non-O blood 
types have a higher incidence of stomach and pancreatic cancer as compared to O 
blood type.  Pancreatic cancer in particular has been studied extensively, and it 
has been concluded that polymorphisms in the ABO gene affect an individual’s 
susceptibility to the disease, but do not cause cancer per se (3). 
 ABO blood type is also associated with cardiovascular disease (CVD).  In 
a study of 4901 patients with CVD, Carpeggiani et al. found a higher prevalence 
of A and B blood types in those who suffered from myocardial infarction (26).  
Non-O blood groups were also a strong predictor of cardiac death, especially in 
patients younger than age 65 and in women.  ABO blood type has also been 
associated with other diseases in which thrombosis plays a part, such as venous 
thromboembolism (VTE).  In a prospective study of two large cohorts, Wolpin et 
al. examined the relationship between blood type and pulmonary embolism (PE), 
specifically (27).  They found that non-O blood types were at a significantly 
increased risk for PE, compared to O blood type.  Research suggests that the 
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increased risk for CVD and VTE observed in non-O blood types is due to 
increased levels of von Willebrand factor, an important intermediary protein 
involved in hemostasis. 
Hemostasis 
 Under normal conditions, the endothelial walls of the blood vessels 
contain anticoagulant components that prevent the adhesion of particles traveling 
in blood.  When the integrity of the vascular walls is compromised by injury, 
blood can quickly escape.  It is imperative that bleeding is stopped as quickly as 
possible.  Hemostasis is the physiological process that stops bleeding. It is a very 
complex mechanism that involves two systems: primary and secondary 
hemostasis. 
 Primary hemostasis is the body’s initial reaction to vascular injury.  It 
involves the aggregation of platelets to form a platelet plug.  When blood vessels 
are damaged, components in the subendothelial matrix are exposed to the blood.  
Receptors on the surface of platelets in the blood are attracted to ligands found in 
the subendothelium.  For example, the platelet receptor glycoprotein Ibα (GPIbα) 
binds to von Willebrand factor (discussed in more detail later) in the 
subendothelium, and receptor glycoprotein VI (GPVI) binds to collagen.  
Receptors GPIbα and GPVI also contribute to the activation of other platelets.  
When platelets are activated, their storage granules undergo exocytosis and 
release a number of factors that promote platelet aggregation, degranulation, and 
vasoconstriction such as adenosine diphosphpate (ADP), thromboxane A2, and 
serotonin.  As platelets adhere to each other and the site of injury, a platelet plug 
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is quickly formed that temporarily seals the blood vessel until a more substantial 
clot can be formed (28). 
 In secondary hemostasis, an insoluble fibrin mesh is deposited in and 
around the platelet plug.  This occurs via a coagulation cascade of chemical 
reactions that is divided into two pathways based on the activation mechanism.  
The extrinsic pathway is initiated by vascular injury and the release of tissue 
factor from damaged tissue.  The intrinsic pathway is initiated by clotting factors 
found in blood.  Both pathways converge into a common pathway, beginning with 
the activation of factor X.  From there, factor X combines with factors III and V 
in the presence of platelet factor 3 and calcium to produce prothrombin activator.  
Prothrombin activator then converts prothrombin to thrombin, and thrombin 
subsequently converts fibrinogen to fibrin (with the help of other cofactors).  In 
most cases, the extrinsic and intrinsic pathways work simultaneously to contribute 
to the formation of the crosslinked fibrin polymer which serves to stabilize and 
strengthen the blood clot (28). 
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Figure 4. Coagulation pathways 
Blood Coagulation Tests 
 The effectiveness of the extrinsic and intrinsic pathways of secondary 
hemostasis, otherwise known as blood coagulation, is commonly measured by 
two separate tests: prothrombin time (PT) and activated partial thromboplastin 
time (aPTT).  These tests are used most frequently in the medical field to assess 
blood coagulation because they are both cheap to perform and accurate in their 
results.  They are used in a number of situations by physicians, including 
preoperative assessment of hemorrhage risk, screening of blood coagulation 
disorders, and monitoring of anticoagulant drug therapies.  Both tests are 
performed on platelet-poor plasma and measure the amount of time it takes for 
blood to coagulate (reported in seconds) after the addition of some agonist (29).   
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The PT test indicates the state of the extrinsic pathway and specifically 
measures the activity of factor VII, a clotting factor that is produced by the liver 
and dependent upon vitamin K.  The drug warfarin is used to inhibit a key enzyme 
in vitamin K metabolism and therefore lessen the risk of blood clots in patients 
with heart problems or risk of embolism.  The PT test is frequently used to 
determine warfarin dosage, the presence of liver dysfunction or disease, and 
vitamin K deficiency.  A normal PT value is between 11.0 and 12.5 seconds.  A 
value below the normal range indicates an increased risk for clotting, whereas a 
higher value signifies an increased risk for bleeding (29, 30).  
The aPTT test evaluates the function of the intrinsic pathway and a variety 
of factors involved in this system.  This assay is commonly used to check the 
efficacy of heparin, another anticoagulant drug.  The normal range for an aPTT 
test is 30 to 40 seconds.  Prolonged aPTT times are associated with a number of 
disorders including congenital bleeding disorders, liver disease, Von Willebrand 
Disease, and leukemia (30).  Shortened aPTT times have been shown to indicate 
hypercoagulability and an increased risk for venous thromboembolism (31). 
Thrombosis 
 Thrombosis, the formation of a blood clot within a blood vessel, is 
responsible for a large portion of morbidity and mortality in the Western world.  It 
is linked to arterial diseases, such as stroke, myocardial infarction and peripheral 
occlusive disease.  It is also related to disorders involved with venous 
thromboembolism, such as deep vein thromboembolism (DVT) and pulmonary 
embolism.  In all of these disease states, a traveling blood clot can potentially 
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occlude smaller blood vessels, eventually leading to an ischemic event that may 
result in death.  Hypercoagulability of the blood is a risk factor for both arterial 
diseases and venous thrombosis (32).  
 The steps involved in hemostasis can be suppressed in order to lessen the 
risk of thrombosis.  This can occur through a few different mechanisms: a 
decrease in cell adhesion molecule expression (such as von Willebrand factor), a 
decrease in molecules that stimulate platelet aggregation (such as thromboxane 
A2), an increase in aggregation inhibitors, the clearance of activated coagulation 
factors, and the inhibition of platelet aggregation (33).  The prevention of 
thrombosis is a fine balance between lessening the risk of clot formation while 
avoiding an increased risk of hemorrhage.  Using diet may offer subtle protection 
against thrombosis without interfering with hemostasis (32). 
Von Willebrand Factor 
Structure and Function 
 Von Willebrand factor (VWF) is a glycoprotein that plays a key role in 
blood hemostasis.  VWF can exist in very large, multimeric forms, making it the 
largest protein in human plasma.  A pro-VWF monomer consists of 2050 amino 
acids, up to 22 carbohydrate side chains, and discrete domains that exhibit 
specific functions.  VWF is produced by the endothelial cells of the blood vessels 
and the megakaryocytes (bone marrow cells) from which platelets are formed.  In 
the endoplasmic reticulum of the cells, two pro-VWF monomers combine to form 
a dimer via a disulphide bond at their C-terminal region.  Then the pro-VWF 
dimers move to the Golgi apparatus to be packaged as very large multimers via 
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disulphide bonds at the N-terminal end of the dimer.  Once formed, VWF 
multimers are packed in storage organelles called α-granules in platelets and 
Weibel-Palade bodies in endothelial cells.  VWF is also secreted into plasma 
constitutively by endothelial cells and is present in the subendothelial connective 
tissue of blood vessels bound to collagen.  When stimulated by an agonist, such as 
thrombin, epinephrine, or ADP, the VWF multimers are released from the storage 
granules.  Eventually, VWF is cleared from plasma by the liver.  VWF serves two 
main functions: 1) it functions as an intermediary adhesive molecule in primary 
hemostasis, and 2) it binds and protects factor VIII (FVIII) in plasma (34-36). 
 In its role in primary hemostasis, VWF serves as an adhesive molecule 
that allows exposed collagen in damaged blood vessels to bind to platelets, as 
discussed above.  Large VWF multimers have an affinity for collagen and 
activated platelets 100-times higher than that of VWF monomers.  This allows 
platelets to aggregate under conditions of high shear rates (36).  Shear rate is the 
difference in blood flow velocity as a function of distance from the vascular wall.  
The velocity of blood at the center of the vessel is faster than it is at the wall, 
which creates a shearing effect that is greatest at the wall.  The highest shear rates 
(up to 5000 s
-1
) are observed at the luminal surface of small arterioles with a 
diameter less than 50 µm.  Shear rates are also significantly higher in stenosed 
arteries, as in the case of progressed atherosclerosis.  VWF is essential for platelet 
aggregation at high shear rates, but not necessarily at lower shear rates (35). 
Storage of large multimer VWF and subsequent secretion upon vascular 
injury allows for maximal function when rapid platelet aggregation and adhesion 
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is necessary.  Adhesion occurs at the A1 domain of the VWF protein, which can 
bind to both collagen and the GPIbα receptor on platelets.  The interaction of the 
A1 domain on VWF and the GPIbα receptor on platelets is also important for 
platelet-to-platelet interactions because it activates integrin αIIbβ3 receptors on 
platelets, which can subsequently bind to the C1 domain of VWF and instigate 
platelet aggregation (see Figure 5).  Once released from storage, VWF undergoes 
reduction in multimer size by the action of plasma proteases, such as ADAMTS-
13 (a disintegrin and metalloproteinase with thrombospondin type-1 repeats).  
ADAMTS-13 protects against uncontrolled platelet adhesion by free VWF 
multimers.  As mentioned above, it is thought that VWF is ultimately cleared 
from plasma by the liver (34, 35). 
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Figure 5. Function of VWF in platelet adhesion and aggregation 
 In its second function of binding FVIII, VWF protects the clotting factor 
from proteolytic degradation in plasma.  VWF can bind to a FVIII molecule at 
two different binding domains: Dʹ and D3.  As its carrier, VWF prolongs the half-
life of FVIII and helps to localize it to the site of vascular lesion.  FVIII is 
responsible for activating factor X in the intrinsic pathway of blood coagulation.  
A deficiency in FVIII leads to classical hemophilia (hemophilia A), a serious 
bleeding disorder (28, 34, 37). 
Von Willebrand Disease 
 A deficiency or defect in VWF leads to a bleeding disorder known as Von 
Willebrand Disease (VWD).  VWD is the most frequently inherited hemostatic 
disorder, but it can also be acquired over one’s lifetime due to other health issues.  
The inherited forms are categorized into three types (type 1, 2, and 3) and type 2 
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is further subdivided into 4 categories (2A, 2B, 2M, and 2N).  Categorization is 
based on mutations in the genes that code for VWF and the cellular machinery 
responsible for assembling and processing it.  Type 1 VWD is the most common 
form of the disease and comprises 60% to 80% of all cases.  In type 1, VWF 
concentration in plasma is low, causing symptoms such as mild bleeding in skin 
and mucous membranes (e.g. easy bruising, bleeding gums, and nose bleeds).  In 
type 2 VWD, plasma VWF concentration is normal but there are structural and 
functional issues with the clotting factor that result in minor bleeding issues.  
Individuals with type 1 or type 2 VWD lead relatively normal lives.  On the other 
hand, Type 3 VWD is associated with a complete absence of VWF in plasma, due 
to a recessive genetic mutation.  Individuals with type 3 VWD suffer from severe 
mucosal bleeding from the time they are born.  Unlike the three inherited forms of 
VWD, the disease can also come about because of other disease states.  For 
example, individuals suffering from aortic stenosis can develop acquired VWD 
and associated intestinal bleeding.  VWD treatments include the use of 
antifibrinolytic drugs to inhibit the premature breakdown of clots, intravenous 
VWF replacement therapy, and desmopressin (a synthetic derivative of 
vasopressin which stimulates endothelial cells to release VWF) (37). 
VWF and ABO Blood Type 
 Interestingly, the most important determinant of VWF level in plasma is 
ABO blood type.  Like red blood cells, VWF molecules also present A and B 
blood group antigens attached to N-linked oligosaccharide side chains.  Current 
evidence suggests that the presence of these antigens slows the clearance of VWF, 
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so non-O blood group individuals have higher concentrations.  It has been 
speculated that non-O blood types have 25% more VWF in their plasma when 
compared to O blood type (36).  In a large study of twins, Orstavik et al. found 
that 66% of the variation in plasma levels of VWF was genetically determined, 
and 30% of that was contributable to ABO blood group (38).  In normal 
individuals, blood group O has VWF antigen levels of 65.4 to 102.8 IU/dl, with 
most levels falling below 90 IU/dl.  On the other hand, group A, B and AB 
individuals have an average of 90 to 139 IU/dl of VWF antigen (39). 
Some studies have investigated the difference in VWF levels among ABO 
blood group subcategories.  For example, Souto et al. found that individuals with 
a homozygous genotype for blood group O (OO) demonstrated the lowest level of 
VWF.  Also, individuals who were heterozygous for the O allele (AO and BO) 
had significantly lower levels of VWF in plasma compared to individuals without 
an O allele (AA, BB, and AB) (40).  Given the increased levels of VWF seen in 
non-O blood types, a good deal of research has investigated the associated risk of 
thrombosis. 
VWF, ABO Blood Group, and Risk of Thrombosis 
 Beginning in the 1990s, researchers began to study the relationship 
between high plasma concentrations of VWF and risk of arterial and venous 
thrombosis.  A larger portion of the research has focused on arterial thrombosis, 
specifically.  One of the more recent studies conducted was the Prospective 
Epidemiological Study of Myocardial Infarction (PRIME), published in 2004 
(41).  It followed 9,758 healthy men aged 50 to 59 years old for a total of five 
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years.  Men with VWF levels in the top 25% experienced a risk of coronary heart 
disease (CHD) three times higher compared to men with VWF levels in the 
lowest 25% of study subjects.  Even after adjusting for inflammatory markers 
such as C-reactive protein, interleukin-6, and fibrinogen, the value of VWF as an 
independent risk factor for CHD remained the same.  Likewise, in a meta-analysis 
conducted by Whincup et al. in 2002, previous prospective studies looking at 
VWF and CHD were analyzed.  They found that subjects who fell in the top third 
of baseline VWF values had a combined odds ratio for CHD of 1.5 compared to 
subjects in the bottom third (95% confidence interval, 1.1 to 2.0) (42).   
In another meta-analysis published by Wu et al. in 2008, investigators 
tried to elucidate the relationship between ABO blood group, VWF levels, and 
risk of arterial thrombotic complications, such as myocardial infarction (MI) (39).  
They found a significant association between non-O blood types and risk of MI 
(pooled OR of 1.25, 95% confidence interval, 1.14 to 1.36); however this 
association was only seen in retrospective studies.  Wu and his colleagues also 
found an increased risk in non-O blood types for peripheral vascular disease 
(PVD) (pooled OR of 1.45, 95% confidence interval, 1.35 to 1.56) and cerebral 
ischemia of arterial origin (CIAO) (pooled OR of 1.14, 95% confidence interval, 
1.01 to 1.27).  Although a causal relationship between VWF, ABO blood group, 
and arterial thrombosis seems plausible, the current body of research lacks well-
designed prospective studies to confirm the nature of the relationship.  It may be 
that VWF levels are simply a reflection of preexisting endothelial dysfunction, 
which leads to atherosclerosis and ensuing arterial thrombosis (6).      
  26 
 Raised levels of VWF have also been linked to venous thrombosis, 
although fewer studies have looked at this connection when compared to arterial 
thrombosis (34).  In 1995 Koster et al. studied 301 subjects over 70 years old who 
suffered from a primary episode of VTE compared to 301 controls (43).  A 
univariate analysis showed that high concentrations of VWF and FVIII, along 
with non-O blood group, were all risk factors related to DVT.  However, in a 
multivariate analysis, only FVIII remained a significant risk factor.  Their study 
suggests that VWF and ABO blood group may confer risk for VTE, but their 
effects are mediated through the function of FVIII in the coagulation pathway 
(recall that VWF is the carrier for FVIII and serves to lengthen the clotting 
factor’s half-life).  In another study named the Longitudinal Investigation of 
Thromboembolism Etiology (LITE) published in 2002, Tsai et al. followed 
19,237 healthy individuals over the age of 45 for an average of 7.8 years.  Of the 
159 VTE events that occurred over this time period, both VWF and FVIII were 
found to be independently linked in a dose-dependent manner to an increased risk 
for development of VTE.  Individuals in the highest quartile of VWF 
concentrations saw a hazards ratio of 4.6 (95% confidence interval, 2.2 to 9.2).  
Furthermore, in the systematic review and meta-analysis by Wu et al. mentioned 
above, researchers also analyzed 21 studies on blood group and VTE (39).  
Although there was significant heterogeneity between studies, all but three found 
that non-O blood groups bore a significantly increased risk for VTE, with an odds 
ratio of 1.75 (95% confidence interval, 1.51 to 2.03).   
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 Data from numerous studies point towards a possible causal relationship 
between VWF, blood group, and thrombosis, particularly with venous thrombosis.  
This has raised the question of whether there would be value in assessing blood 
type when screening patients for risk of thrombosis, but further research is 
required to establish the particular risk associated with various blood group 
genotypes and phenotypes (44).  Whereas universal screening may not be 
clinically or cost effective, there is some suggestion that selective screening of 
ABO blood type, in addition to routine thrombophilia tests, may prove useful in 
identifying individuals at risk (particularly AA, BB, and AB genotypes) (39). 
Other Factors that Raise VWF Concentration 
 Although ABO blood group has proven to be the most influential factor on 
blood concentration of VWF, it is not the only one.  For example, genetic 
mutations in the enzymes that process VWF, such as metalloprotease ADAMTS-
13, can significantly affect the amount of VWF and the size of its multimers in 
plasma.  A congenital or acquired deficiency of ADAMTS-13 results in very large 
VWF multimers that form platelet-rich thrombi in small blood vessels, leading to 
a disease known as thrombotic thrombocytopenic purpura (TTP).  In this disease, 
the constant formation of platelet-rich clots leads to low platelet counts in plasma.  
The lack of available platelets can lead to bleeding in other parts of the body 
(such as the skin, leading to small purple spots called “purpura”).  Because 
ADAMTS-13 does not function properly in TTP, VWF levels are unusually high 
in those with the disease (34). 
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 Chronically high concentrations of VWF have also been seen in older age.  
This may be caused by arterial rigidity, but the precise mechanism is not well 
understood.  Certain chronic health conditions also raise levels of VWF including 
obesity, hypertension, diabetes, chronic inflammation, rheumatoid arthritis, 
cancer, liver disease, and renal disease.  Temporary health conditions, such as 
pregnancy, surgery, and exercise have also been shown to raise VWF 
concentration.  Some hormones and their synthetic forms can also raise VWF, 
such as epinephrine, vasopressin, and desmopressin (6, 34). 
Dietary Intervention and Hemostasis 
 The relationship between diet and hemostasis has been explored by a 
number of studies.  In some, a complete dietary approach has been used as the 
independent variable, such as vegetarians versus meat eaters.  In other studies, 
singular foods have been looked at or even particular food components such as 
fatty acids, vitamins, and phytochemicals.  The following section reviews the 
literature available on dietary intervention and its effect on blood clotting. 
Whole Diets 
Mediterranean Diet 
 The Mediterranean diet is modeled after the style of eating practiced in the 
countries surrounding the Mediterranean Sea.  The main components of the diet 
are healthy fats (such as olive oil), fish, fruits and vegetables, and wine.  The 
benefits of this way of eating on heart health have been widely studied.  For 
instance, in a study published by Passaro et al. in 2008, middle-aged women with 
moderate risk for CVD followed a Mediterranean-like diet.  The study began with 
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a washout period of three weeks which had the subjects adhere to an isocaloric 
diet.  After this phase, they began a diet that emphasized dry white wine, extra 
virgin olive oil, salmon, nuts and carbohydrates low on the glycemic index.  After 
following the diet for three weeks, there was another washout period of three 
weeks during which the subjects returned to the isocaloric diet.  The researchers 
measured various hemostatic factors in addition to other know markers for CVD 
risk.  Most notably, they saw factor VII and factor VIII levels decrease in those on 
the diet, which in turn reduced levels of tissue factors.  Thrombin generation 
times were also extended after dietary intervention.  However, levels of 
fibrinogen and VWF were not significantly changed (45). 
Vegetarian Diet 
 Plant based diets have been shown in some cases to improve hemostatic 
measures.  For example, a few cross-sectional studies have been conducted over 
the past thirty years that showed favorable hemostatic conditions for vegetarians 
versus non-vegetarians.  The earliest, conducted by Haines et al. in 1980, found 
that vegetarian participants had significantly lower levels of clotting factor VII in 
both males and females (46).  A later study in 1999 by Famodu et al. looked at 
black, vegetarian Seventh-Day Adventists compared to non-vegetarians in nearby 
communities.  In vegetarian subjects, they found fibrinogen levels to be 
significantly lower, suggesting a lower risk for arterial thrombosis.  Also, the 
vegetarians had significantly higher fibrinolytic activity, which the authors 
suggested was due to their higher fiber intake (47).  Likewise, in a study by 
Mezzano et al. in 1999, the researchers found that factor VII and fibrinogen levels 
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were lower in vegetarians compared to non-vegetarians.  On the other hand, the 
vegetarians had increased platelet aggregation times.  The authors suggested this 
was due to the low consumption of anti-inflammatory eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) in vegetarians, two fatty acids that 
displace arachidonic acid (AA) in platelet membranes.  AA is a precursor to 
thromboxane A2, which is a key factor in platelet aggregation (48).   
Not all studies have shown a difference in clotting measures between 
vegetarians and meat eaters.  For example, in a cross-sectional comparison 
performed by Li et al. in 1999, the researchers compared thrombotic risk factors 
in vegetarian men with their meat-eating counterparts.  The researchers 
hypothesized that the meat eaters would have higher levels of blood markers that 
indicate increased thrombotic risk, due to the higher intake of AA from eggs and 
meat.  However, they did not see an increased risk for platelet aggregation in the 
meat eaters, perhaps due to their higher intake of EPA and DHA also suggested 
by Mezzano et al. (49).   
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Whole Foods 
Fish 
 See “Fatty Acid” section below. 
Fruits and Vegetables 
 Although diets high in fruits and vegetables have been recognized to lower 
the risk of CVD, the possibility that this occurs due to antithrombotic effects of 
fruits and vegetables has not been studied extensively.  In 2004, Freese et al. 
published a study which explored the antithrombic effects of vegetables, berries 
and apples.  The study included healthy men and women divided into four groups: 
two who consumed a diet high in vegetables, berries and apples, and two with a 
diet poor in those foods.  In addition, the two experimental groups were further 
divided into diets rich in linoleic acid or oleic acid, as were the two control 
groups.  The groups followed their prescribed diet for six weeks.  The researchers 
performed many hemostatic measures, including platelet aggregation, but found 
no difference in platelet and endothelium markers between the four groups (50).   
Garlic and Onion 
 Garlic and onion are members of the allium plant species, and contain a 
number of compounds with high sulfur content.  Research has shown that some of 
these compounds inhibit platelet aggregation.  These effects are greatest when the 
sulfur levels are high and the garlic and/or onion is served raw.  Onion and garlic 
preparations appear to inhibit the production of thromboxane from its AA 
precursor, an important factor in platelet aggregation discussed above (32).  In 
addition, a component of garlic called ajoene appears to interfere with the binding 
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of VWF and fibrinogen to platelets by reducing the number of GPIIb/IIIa 
receptors sites on the platelet membrane (51).   
Ginger 
 Ginger and its extracts have been shown to inhibit platelet aggregation.  It 
is believed that the components in ginger exhibiting these effects are the gingerols 
and shogaols that form during storage and cooking (32).  These pungent 
constituents appear to inhibit AA metabolism, as do the compounds in garlic and 
onions discussed above.  However, most experimentation has been performed in 
vitro, and results from human in vivo studies are less conclusive.  Experiments on 
rats that administered high levels of ginger extract (500 mg/kg) reduced 
thromboxane B2 levels (52), however, experiments with humans consuming raw 
(5-15 g/day) and cooked (40 g/day) ginger for one to two weeks had no effect of 
thromboxane B2 concentration in serum (53).  
Soy 
 The effect of soy on hemostasis and thrombosis has not been studied much 
in human subjects.  In an animal study published in 2006, Sawashita et al. fed 
apolipoprotein E (apoE)-deficient mice an eight week diet of varying protein 
powders derived from soy, pork, egg, chicken, or fish.  They found that the mice 
fed soy protein exhibited a significant antithrombic effect, although they 
contributed it to the hindrance of atherosclerosis instead of the inhibition of 
platelets.  At the end of the eight weeks, they also found that pork protein had a 
prothrombic effect (54).  
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 Soy contains a polyphenol named genistein that has been studied in 
relation to thrombosis.  Refer to the “Genistein” section below for further detail. 
Tomatoes 
 A link between tomatoes and lower risk of heart disease has been reported 
in epidemiological studies.  Note that tomatoes are a major ingredient in the 
Mediterranean Diet discussed previously.  Tomatoes are the major dietary source 
of the carotenoid lycopene.  Although blood levels of lycopene have been 
inversely correlated with the early development of atherosclerosis, coronary 
events and CVD mortality, it is not known exactly how tomatoes are conferring 
this protective effect (32).  Research suggests that these benefits may be via 
inhibition of platelet aggregation, among other mechanisms.  For example, in a 
study by Lazarus et al. in 2004, individuals with type 2 diabetes who had 
hyperactive platelets were given a tomato extract supplement that significantly 
reduced platelet aggregation.  Contrary to expected reasoning, the researchers 
reported that lycopene was not the responsible component (55). 
Wine 
 See “Resveratrol” section below. 
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Nutrients 
Carbohydrates 
 The intake of carbohydrates is the principle driver of postprandial insulin 
concentration.  It has been shown that insulin stimulates the production of 
plasminogen activator inhibitor (PAI-1).  PAI-1 inhibits fibrinolysis, an important 
step in the breakdown of clots.  Therefore, increased insulin levels have been 
associated with the development of atherothrombosis (56).  Replacing high 
glycemic index (GI) foods (such as white bread) with low GI foods (such as 
multi-grain bread) may reduce the risk of thrombogenesis (57). 
Fatty Acids 
 Monounsaturated fatty acids (MUFA) that are present in plant-based oils 
such as canola oil and olive oil may have a favorable impact on thrombotic and 
hemostatic measures.  For example, Larsen et al. conducted a randomized 
crossover trial in 1999 during which healthy adults ate a diet rich in rapeseed oil, 
sunflower oil, or olive oil for a total of three weeks.  The oils vary in their fatty 
acid composition: rapeseed oil is high in both MUFA and omega-6 (n-6) 
polyunsaturated fatty acid (PUFA); sunflower oil is high in n-6 PUFA; and olive 
oil is high in MUFA.  Subjects who followed the olive oil diet had significantly 
lower levels of factor VII compared to the sunflower oil group.  A similar trend 
was seen when compared with the rapeseed oil group, although the difference did 
not reach significance (58).  The Mediterranean Diet, discussed above, is known 
to have high levels of olive oil and has also been shown to lower factor VII levels 
(45, 59). 
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 The effect of omega-3 (n-3) PUFAs on hemostasis has been studied 
extensively.  N-3 PUFAs are present in fatty fish, such as salmon, along with EPA 
and DHA.  The consumption of fish is inversely related to the incidence of CVD 
(60).  Supplementation of fish oil increases the ratio of n-3 to n-6 fatty acids in 
human tissue, including platelets, and has been shown to inhibit platelet 
aggregation (32).  EPA displaces AA in the platelet membrane, and therefore 
inhibits the production of active thromboxane, as discussed previously. 
Vitamin E 
 Increased vitamin E intake has been associated with a decreased incidence 
of coronary events.  Among other mechanisms, the inhibition of platelet adhesion 
and aggregation has been suggested as a reason behind this phenomenon.  Studies 
performed in vitro have demonstrated that lipid peroxidation is inhibited by α-
tocopherol (a form of vitamin E) and therefore reduces the release and 
aggregation of platelets (61).  However, in a study conducted by Dereska et al. in 
2005, healthy adult subjects showed no change in platelet aggregation or bleeding 
times in vivo (62).  They speculated that the effects of α-tocopherol in vitro on 
platelet aggregation may not be reproducible in human subjects. 
Vitamin K 
 Various proteins in the body need vitamin K to convert to their active 
forms, including blood clotting factors such as prothrombin, factor VII, factor IX, 
and factor X.  Anticoagulant medications, such as warfarin, interfere with the 
recycling of vitamin K and therefore inhibit blood clotting.  Patients on warfarin 
are often instructed to avoid eating high vitamin K foods in excess, such as dark 
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leafy greens.  However, oral supplementation of vitamin K has been shown to be 
an effective and safe way to ameliorate excessive hemorrhagic effects from 
warfarin (63, 64).  The important role of vitamin K in thrombogenesis has been 
well established (32). 
Polyphenols 
 Polyphenols are a broad class of molecules that share the structural 
commonality of containing more than one phenolic hydroxyl group.  Although 
polyphenols are not considered nutrients, they are molecules that play beneficial 
roles in the human body through various mechanisms.  High consumption of 
foods rich in polyphenols is inversely associated with death caused by thrombosis 
and IHD (8).   
Flavanols and Proanthocyanidins 
 Flavanols are a type of polyphenol found in plant foods such as cocoa, red 
wine, grape seeds, and green tea.  Flavanols can exist as single compounds, 
known as catechins, or oligomeric compounds, known as proanthocyanidins.  In 
an epidemiological study of elderly men by Arts et al. in 2001, intake of catechin 
rich foods (such as black tea, apples, and chocolate) was inversely related to 
mortality from IHD (65).  Besides exhibiting antioxidant and anti-inflammatory 
benefits, polyphenols have been shown to inhibit platelet activation and 
aggregation.  For example, in a crossover study by Pearson et al. in 2002, healthy 
adult subjects consumed cocoa (rich in flavanols and proanthocyanidins), aspirin, 
or a combination of the two.  The researchers performed tests on platelet 
activation and function at two and six hours after ingestion.  The cocoa was found 
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to significantly inhibit platelet function, although the effects were less pronounced 
than those of aspirin (66). 
Genistein 
 Genistein is an isoflavonoid found in soy foods.  In vitro studies have 
shown that genistein interferes with platelet function and the action of thrombin.  
Via these mechanisms, it has been suggested that genistein may have the 
capability of altering blood coagulation and subsequently mitigating the 
progression of atherosclerosis (67).  Human experimental trials on soy and 
genistein are limited, but effects have been studied in animals.  For example, in 
2002 Kondo et al. tested the ability of genistein to inhibit femoral artery occlusion 
in mice, in vivo.  In addition, they measured in vitro platelet aggregation.  They 
found that genistein prolonged the time to vessel occlusion and inhibited platelet 
aggregation.  These results suggest that eating soy foods can moderate the 
progression of thrombosis and atherosclerosis (68). 
Resveratrol 
  Resveratrol is a polyphenol found in the skin of red grapes and in red 
wine.  It has been the topic of much recent study, due to the link between red wine 
consumption and a reduced risk of CVD.  This has been described in the literature 
as the “French paradox” because the French consume relatively high amounts of 
saturated fat but have a low incidence of CVD.  A protective effect was attributed 
to their high consumption of red wine (69).  Resveratrol in red wine and purple 
grape juice has been found to interfere with platelet function.  For example, in a 
randomized cross-over study by Keevil et al. in 2000, healthy adults consumed 
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either purple grape juice, orange juice, or grapefruit juice daily for 7 to 10 days.  
They found that the purple grape juice significantly reduced platelet aggregation, 
while there was no effect in the other groups.  The purple grape fruit juice had 
three times the polyphenol concentration of the other juices (70). 
The Blood Type Diet 
 In 1996, naturopathic doctor Peter J. D’Adamo published the diet book 
“Eat Right 4 Your Type” and has since sold over 5 million copies in more than 50 
languages (1).  In the book, D’Adamo suggests that people should be eating 
specialized diets based on their blood type.  This idea was first set forth by his 
father, who was also a naturopathic doctor.  The two developed their theory on 
blood type diets based on anecdotal evidence collected from patients.  D’Adamo 
claims that patients who have followed his diets have experienced more energy, 
weight loss, improved digestion, and relief from chronic ailments such as 
heartburn, asthma and headaches.  He states that the diets are “designed for 
optimal performance” (2). 
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Lectins 
 Lectins are proteins that have an affinity for binding carbohydrates.  They 
are common in plant foods such as beans and grains.  They have the ability to 
agglutinate human cells, and have been show to resist protein breakdown initiated 
by heat from cooking or digestive enzymes (71).  The theory behind the blood 
type diet is that lectins interact with ABO blood cell antigens and can potentially 
cause the cells to agglutinate, resulting in various adverse health effects.  
Therefore, foods with lectins that would cause this interaction with a particular 
ABO antigen should be avoided by individuals of that type.  D’Adamo writes that 
he has performed numerous tests with lectins from various foods in which he 
mixed them with blood samples and observed the results under a microscope.  In 
a reactive blood type, D’Adamo observed the RBCs agglutinating (2).  
D’Adamo’s findings have not been published in peer-reviewed journals. 
 However, research has been published on the interaction of dietary lectins 
and blood cell antigens.  For example, in 2002 Evans et al. published a case-
control study looking at intake of galactose (found in fruit and vegetable fiber) 
and risk for colorectal cancer.  The researchers hypothesized that galactose 
conferred a reduction in risk by binding a blood cell antigen known as Thomsen 
Friedenreich (TF), which is expressed by precancerous and cancerous epithelial 
cells in the colon and rectum.  As the theory goes, the binding of galactose to the 
TF antigen may inhibit the binding of dietary or microbial lectins that would 
cause the cancerous cells to proliferate (72).  In a previous study, researchers were 
able to show that a peanut lectin caused such proliferation (73).  Indeed, Evans et 
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al. found that subjects in the highest quartile of galactose consumption saw a 
significantly lower odds ratio for colorectal cancer.   
Interestingly, in an associated study, whole peanut lectins were found in 
the peripheral venous blood of subjects who ingested peanuts one to four hours 
before the blood draw (71).  This demonstrates that some lectins can avoid 
digestion and go past the gut into circulation, completely intact.  Other research 
has also shown that lectins from cereals and legumes can interact with the gut to 
increase its permeability, allowing bacterial and dietary antigens to enter into 
circulation (74).  These finding are in line with D’Adamo’s statement that lectins 
can enter the blood stream and affect cells beyond the digestive tract.  However, 
research indicates that lectins very rarely have a high affinity for one singular 
ABO blood cell antigen, with the exception of some beans (3). 
 A commentary on dietary lectins and disease published in the British 
Medical Journal by allergist David Freed points out associations between dietary 
lectins and diseases such as celiac disease, type 1 diabetes, rheumatoid arthritis, 
and peptic ulcer.  He described how the attachment of certain dietary lectins to 
various cells can elicit an autoimmune response that leads to the aforementioned 
conditions (75).  However, much of the research he reported on was speculative 
and further investigation is warranted. 
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Individualized Diets 
Each blood type – O, A, B, and AB – has its own chapter in the book in 
which D’Adamo prescribes what foods should and should not be eaten.  He 
divides each of the food groups into three categories: “highly beneficial,” 
“neutral,” and “avoid.”  He instructs the reader to eat mostly from the highly 
beneficial foods, occasionally from the neutral foods, and never from the foods to 
be avoided.  Foods in the “avoid” category supposedly contain the lectins harmful 
to that particular blood type.  Each diet is described in general terms below: 
 Type Os are the meat eaters.  They do well with plenty of animal protein, 
but should avoid dairy and most grains. 
 Type As are the vegetarians.  They thrive on plant-based protein such as 
soy, and are more tolerant of a wide range of grains.  Like type Os, they 
should also avoid dairy. 
 Type Bs have the most flexibility in their diet and can consume a variety 
of items.  For example, they can consume dairy products and meat, 
although there are some odd restrictions, such as chicken and pork.  
 Type ABs are considered a combination of types A and B.  Many of their 
dietary restrictions are the same as those of the previous two types. 
Dr. D’Adamo’s diet is regarded as “pseudo-science” in the literature and 
has not been properly corroborated by science (3, 74), but the popularity of his 
book warrants scientific investigation so that the public may be better informed 
before taking his advice to heart. 
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Chapter 3 
METHODS 
Study Design and Subjects 
 This study was a randomized, parallel arm, dietary intervention using 
healthy, omnivorous adults with blood types A and O.  The study was approved 
by the Arizona State University Institutional Review Board (see Appendix A for 
IRB approval).  Study volunteers were recruited largely from the ASU downtown 
campus via email invitation distributed on the ASU nutrition listserv and 
recruitment flyers posted on campus.  The goal was to enroll 60 subjects in hopes 
of retaining at least 40 by the end of the study, based on a review of sample size 
in similar studies.  Potential subjects were initially screened by an online survey 
posted on Survey Monkey™ to eliminate candidates that did not meet inclusion 
criteria.  Out of 104 people who responded to the online survey, 24 did not qualify 
because they met one or more of the exclusion criteria listed in the following 
paragraph.  The remaining 80 people were invited via email to an in-person 
screening at ASU’s downtown campus.  Forty-eight individuals attended the in-
person screening and were admitted into the study.  Informed written consent was 
obtained from each subject after the study objective, benefits, and risks were 
thoroughly explained (see Consent Form in Appendix A).   
Participants were over 18 years old and in good health.  Exclusion criteria 
included smoking habit, previous history of bleeding diathesis, such as 
hemophilia; hypertension (blood pressure greater than 140/90 mmHg); a 
previously recorded abnormal bleeding time; abnormally high or low platelet 
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count; ingestion of over-the-counter anticoagulant medication such as aspirin and 
other non-steroidal anti-inflammatory drugs (NSAIDs) within two weeks of the 
start of the trial; ingestion of prescription anticoagulant medications such as 
Coumadin, sulfinpyrazone or dipyridamole; injection of heparin or dextran in the 
two weeks prior to the study; recent liver disease; collagen vascular diseases such 
as lupus; cancer; current pregnancy; antibiotic use within the two weeks prior to 
the study or history of chronic ingestion of antibiotics; and known vitamin K 
deficiency (62).  Furthermore, study subjects could not practice vegetarianism and 
confirmed consumption of meat and dairy products daily via a food frequency 
questionnaire at the in-person screening.  Participants were willing to omit meats 
(with the exception of chicken, turkey, and fish) and all dairy products from their 
diet, and consume soy products every day for four weeks.  
 One of the individuals who attended the in-person screening and signed 
the consent form dropped out (citing a lack of time) before the researchers 
randomized subjects into study groups.  A total of 47 subjects (23 with blood type 
A and 24 with blood type O) were stratified by blood type and weight and 
subsequently randomized into two groups: an experimental group made up of 12 
type A individuals and 12 type O individuals that adhered to the type A, 
vegetarian-like diet for four weeks, and a control group made up of 11 type A 
individuals and 12 type O individuals that continued their normal, omnivorous 
diet for the duration of the study (see Figure 6).   
 Eight more subjects withdrew over the course of the study.  Five 
individuals cited scheduling conflicts and lack of time and three women found out 
  44 
they were pregnant and were therefore excluded.  A total of 39 subjects completed 
the study. 
 
Figure 6. Study design 
Diet 
 Half of the type A subjects and half of the type O subjects comprised the 
intervention group that followed the type A diet plan as described in D’Adamo’s 
book, for four weeks (2).  This is a vegetarian-like diet that focuses on soy 
proteins, vegetables, and grains.  However, it is not completely meatless because 
some fish and poultry are allowed.  Food sources should also be consumed in as 
natural a state as possible, avoiding processed and refined foods.  For a complete 
description of the diet, see the Diet Guidelines handout provided to subjects in 
Appendix B.  The control group followed their normal, omnivorous diet during 
the four week study period.  Subjects in the vegetarian-like diet group were 
provided with 28 servings of soy milk packaged in 8 oz aseptic containers, to be 
consumed once a day.  The remaining soy milk was distributed to the control diet 
group at the conclusion of the study. 
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Study Protocol 
 After initial screening by online survey, potential subjects visited the ASU 
downtown campus for an in-person screening.  After their consent was obtained, 
they filled out questionnaires regarding medical history and food frequency to 
confirm meat and dairy consumption (see Appendix B for copies of the 
questionnaires).  If they could not provide a validated blood donor card or other 
official documentation of blood type, a finger prick test was performed to assess 
blood type.  Age, weight, height, and blood pressure were also recorded. 
 All blood type A and O individuals who qualified for the study were 
stratified by blood type and weight and then randomized into the vegetarian-like 
diet group or control diet group.  Participants were asked to abstain from the use 
of prescription and over the counter medications, including aspirin and NSAIDs, 
for two weeks following the in-person screening, per Dereska et al. (62).  During 
this time, subjects continued to eat their normal diet.  Both study groups returned 
to ASU after two weeks to have their blood drawn at week 0 of the study. 
In addition to a blood draw, subjects also were weighed again and given a 
$10 Target gift card.  Those in the vegetarian-like diet group received detailed 
instruction on the type A diet and were given a 28 day supply of 8 oz vanilla soy 
milk.  In addition to a detailed Diet Guidelines handout and a Meal Replacement 
Guide, experimental subjects were also given a Compliance Calendar and asked 
to place an ‘X’ on the dates they complied and to note non-compliant foods and 
serving size on days they did not.  All of these handouts can be found in 
Appendix B. 
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   After this visit, the vegetarian-like diet group began the type A diet while 
the control diet group maintained their usual, omnivorous diet.  Weekly follow up 
emails were sent to the vegetarian-like diet group to encourage compliance.  At 
week 4 both groups returned to ASU to have their blood drawn again.  In 
addition, their weight was recorded, a food frequency questionnaire was 
completed, and they received another $10 Target gift card.  Leftover soy milk was 
divided and distributed among the returning control diet group subjects.   
For more detail on study protocol, see the timeline in Appendix C. 
Laboratory Analysis 
 Blood type was determined from whole blood obtained from a finger prick 
using an EldonCard™ 2511-1 ABO-Rh Home Blood Typing Test Kit (Craig 
Medical Distribution Inc., Vista, CA).  Venous whole blood was drawn from all 
study subjects at week 0 and week 4 of the study.  Blood was collected in tubes 
that contain an anticoagulant, such as citrate, and gently inverted by hand four 
times to ensure proper mixing (62).  In addition to the clotting tests detailed 
below, blood was analyzed for c-reactive protein (CRP) concentration and lipid 
profile using the cobas c 111 analyzer (F. Hoffmann-La Roche Ltd, Switzerland).  
Detailed procedures for all analytical tests performed can be found in Appendix 
D. 
Von Willebrand Factor 
 Von Willebrand factor was analyzed using the von Willebrand factor - 
IMUBIND® vWF ELISA (product number 828, American Diagnostica Inc., 
Stamford, CT).   
  47 
Citrated Whole Blood Coagulation Testing 
 Prothrombin time (PT) and activated partial thromboplastin time (APTT) 
were used to assess the extrinsic and intrinsic blood coagulation pathways, as they 
have been in other dietary intervention studies (62, 76-79).  Both tests were run 
through Sonora Quest Laboratories in Phoenix, AZ on a Sysmex CA-7000 
analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY).  The Sysmex 
CA-7000 has been evaluated by Fischer et al. and demonstrated an intra- and 
inter-assay coefficient of variation below 5% for most parameters, demonstrating 
satisfactory precision (80).  
Statistical Analysis 
Statistical analysis was performed using SPSS Statistical Analysis system 
19.0 (Chicago, IL).  Results are expressed as mean ± standard deviation.  
Statistical differences between the experimental and control groups, as well as 
blood type groups, were calculated by two-way, between-group analysis of 
variance (ANOVA).  Attempts were made to normalize values that did not 
conform to a normal distribution.  Differences were considered significant at P < 
0.05. 
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Chapter 4 
RESULTS 
Baseline Data 
 Of the 39 subjects who completed the study, 19 were blood type O and 20 
were blood type A.  There were 34 women and 5 men, with an average age of 
27.5±8.7 years and an average BMI of 24.0±3.7, which is classified as normal.  
There were 27 Caucasians (69%), 6 Hispanics (15%), 3 Asians (8%), 1 African 
American (3%), and 2 subjects who reported their race as “other” or left the 
question blank.  Baseline data (study week 0) were collected at the subjects’ 
second visit, approximately two weeks after their initial in-person screening.  
During that two week interim, subjects abstained from the use of NSAIDs and 
continued their normal eating habits.  In addition to height and weight, a venous 
blood sample was taken at study week 0 and tested for PT, APTT, VWF, CRP, 
and lipid profile.  Week 0 characteristics of the four study groups are presented in 
Table 1.  No significant differences were found between the four groups, with the 
exception of VWF.  Blood type O subjects had significantly lower blood levels of 
VWF compared to blood type A subjects; 690.4±189.7 mU/ml and 1012.1±298.5 
mU/ml, respectively (p<0.001) (see Figure 7). 
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Table 1. Baseline data (study week 0) collected from four study groups
a 
 
 
Variable 
Control  
Type O 
(n=9) 
Control  
Type A 
(n=9) 
Experimental 
Type O 
(n=10) 
Experimental 
Type A 
(n=11) p Value
b
 
Age
 c
 (yr) 26.4±5.8 27.8±10.3 28.0±10.9 27.8±8.1 0.981 
Height (in) 67.3±4.2 64.6±1.7 66.3±2.9 65.6±3.0 0.298 
Weight (lb) 162.2±42.5 138.2±14.7 145.7±20.8 150.1±29.1 0.354 
BMI 25.0±5.3 23.3±2.7 23.3±3.3 24.3±3.3 0.719 
PT (sec) 10.8±0.9 10.7±0.3 10.7±0.3 10.9±0.6 0.739 
APTT (sec) 30.1±1.3 28.8±2.3 30.3±2.0 29.1±2.7 0.344 
VWF 
(mU/ml) 627.7±152.6 991.3±374.1 746.8±209.3 1029.1±237.9 0.003
d
 
Total Chol 
(mg/dl) 165.6±40.6 152.6±29.3 146.8±22.0 152.7±18.6 0.536 
HDL (mg/dl) 53.9±21.4 69.8±16.0 65.6±12.2 60.5±13.1 0.186 
LDL (mg/dl) 105.8±32.6 81.6±24.1 77.1±19.3 89.8±16.6 0.061 
Triglycerides
e
 
(mg/dl) 104.5±35.2 69.7±27.0 78.9±35.4 77.1±24.1 0.134 
hsCRP
c
 
(mg/L) 3.95±4.28 0.94±0.86 1.94±2.84 1.47±1.51 0.219 
Kcal/day 1734±615 1678±480 1581±539 1652±625 0.908 
  
 
aData presented as mean±SD 
bp value represents one-way, between-group ANOVA 
cData transformed to log for normality 
dLSD post hoc test shows significant difference between type O and type A subjects across both diet groups 
eData transformed to square root for normality 
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Compliance 
 In order to assess compliance with the vegetarian-like diet, a food 
frequency questionnaire (FFQ) was designed to isolate foods permitted and 
restricted on the diet.  Subjects recorded the number of servings of each food item 
they ate per week, then stated whether the serving size was small, average, or 
large.  To score the FFQs, the number of servings for each food item was 
multiplied by a number assigned to serving size (small = 0.5, average = 1, and 
large = 1.5), then these scores were added together for the permitted and 
prohibited food categories.  All subjects filled out the FFQ at week 0 and week 4. 
 At week 0, the control diet group had an average score of 50.2±23.1 in the 
category of vegetarian-like diet permitted foods and a score of 52.3±21.0 in the 
restricted foods category.  At week 4, the control group had an average score of 
45.6±20.8 in the permitted foods category and 47.3±18.3 in the restricted foods 
category.  There was no significant difference between the scores at week 0 and 
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week 4 in the control diet group, indicating that the group did not change their 
eating patterns.  
 At week 0, the vegetarian-like diet group had an average score of 
49.9±18.1 in the permitted foods category and a score of 48.4±19.0 in the 
restricted foods category.  At week 4, the vegetarian-like diet group had an 
average score of 80.0±39.0 for permitted foods and 5.2±5.0 for restricted foods.  
There was a significant difference between week 0 and week 4 scores among the 
vegetarian-like diet group (p<0.001), as well as a significant difference between 
permitted and restricted food scores at week 4 (p<0.001), indicating compliance 
to the experimental diet. 
 
 Finally, all subjects in the vegetarian-like diet group filled out a daily 
compliance calendar for four weeks on which they put an ‘X’ for all days they 
complied, or recorded the restricted foods they consumed on days of 
noncompliance.  The number of days they complied was divided by 28 to 
calculate a compliance percentage.  Blood type Os complied 89±9% of all study 
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days whereas blood type As complied 87±7% of all study days.  There was no 
significant difference between type O’s and type A’s compliance percentages. 
Post-intervention Data 
 A table containing all mean data for weeks 0 and 4 can be found in 
Appendix E. 
Clotting Variables 
 A medium negative correlation (Pearson r of -0.350/ p=0.029) existed 
between the change in PT and age.  No other significant relationships between 
descriptors and outcome variables were identified.  Therefore, age was controlled 
for when running the two-way, between-group ANOVA for change in PT.  
Subjects in the experimental group (who followed a vegetarian-like diet for four 
weeks) experienced a significant increase in PT, +0.12±0.32 seconds, whereas the 
control group (who maintained their omnivorous diet for four weeks) saw a 
decrease of -0.06±0.33 seconds (p=0.054).  The vegetarian-like dietary 
intervention had a medium effect size (10.5%) for change in PT.  Furthermore, 
there was a significant difference between the change in PT for type Os in the 
vegetarian-like diet group (+0.24±0.32 seconds) compared to type Os in the 
control diet group (-0.01±0.30 seconds) (p=0.050).  On the other hand, there was 
no significant difference between the change in PT for type As in the vegetarian-
like diet group compared to type As in the control diet group.  Change in PT over 
the course of the four week trial is represented in Figure 8 and mean change±SD 
is reported in Table 2. 
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 No significant change was observed in APTT: the vegetarian-like diet 
group collectively saw an increase of 0.46±1.07 seconds compared to an increase 
of 0.28±1.06 seconds in the control diet group.  Likewise, there was no significant 
change in VWF concentration.  See Table 2 for details. 
 
Table 2. Change in values for blood clotting measures over four weeks in four study 
groups
a
 
 
Variable 
Control  
Type O 
(n=9) 
Control  
Type A 
(n=9) 
Experimental 
Type O 
(n=10) 
Experimental 
Type A 
(n=11) p Value
b
 
PT (sec) -0.01±0.30 -0.10±0.37 0.24±0.32* 0.01±0.28 0.054
c
 
APTT (sec) -0.18±0.85 0.74±1.09 0.45±1.41 0.47±0.70 0.599 
VWF (mU/ml) 260.7±172.4 85.3±245.7 148.3±304.7 215.5±156.7 0.931 
      
 
aData presented as mean±SD 
bp value represents group effect analyzed by two-way, between-group ANOVA 
cControlled for age; *differs significantly from control type O 
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Lipids and CRP 
 Overall, dietary intervention did not result in significant change in the 
subjects’ lipid profiles or CRP levels.  Mean values for change in total cholesterol 
were -7.19±20.14 mg/dl for the vegetarian-like diet group and -3.25±13.40 mg/dl 
for the control diet group.  Mean values for change in HDL cholesterols were -
0.83±5.91 mg/dl for the vegetarian-like diet group and -2.92±7.41 mg/dl for the 
control diet group.  Mean values for change in LDL cholesterol were -4.71±18.09 
mg/dl for the vegetarian-like diet group and -2.04±8.21 mg/dl for the control diet 
group.   Mean values for change in triglycerides were -2.87±20.31 mg/dl for the 
vegetarian-like diet group and 3.58±20.97 mg/dl for the control diet group.  Mean 
values for change in CRP were -0.13±1.81 mg/L in the vegetarian-like diet group 
and -0.53±2.44 mg/L in the control diet group.  For the CRP analyses, two 
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outliers were removed from the data (values >3 SD from mean).  Also, data for 
change in CRP did not fall on a normal curve and was therefore assessed via a 
nonparametric Mann-Whitney U test.  Mean values for study groups reported by 
blood type are listed in Table 3. 
 
Table 3. Change in values for lipid and CRP measures over four weeks in four study 
groups
a
 
 
Variable 
Control  
Type O 
(n=9) 
Control  
Type A 
(n=9) 
Experimental 
Type O 
(n=10) 
Experimental 
Type A 
(n=11) p Value
b
 
Total Chol 
(mg/dl) -3.89±10.83 -2.61±16.23 -0.70±17.99 -13.1±21.0 0.514 
HDL (mg/dl) -5.22±7.58 -0.61±6.88 2.10±5.52 -3.50±5.11 0.278 
LDL (mg/dl) -1.12±5.42 -2.97±10.58 -0.26±16.64 -8.75±19.17 0.599 
Triglycerides 
(mg/dl) -1.79±20.53 8.96±21.16 -2.92±27.56 -2.82±11.88 0.296
c
 
hsCRP
d
 
(mg/L) -0.97±3.16 0.04±0.94 -0.59±2.45 0.30±0.83 0.530
e
 
      
 
aData presented as mean±SD 
bp value represents group effect analyzed by two-way, between-group ANOVA 
cControlled for baseline weight 
dTwo outliers removed because values were out of range 
eData unable to normalize; nonparametric Mann-Whitney U Test used 
 
 
Weight and BMI 
 Subjects in the vegetarian-like diet group lost significantly more weight 
than those in the control diet group, with mean values of -1.4±2.3 pounds and 
+0.7±2.3 pounds respectively (p=0.01).  The vegetarian-like dietary intervention 
had a large effect size for change in weight (17.5%).  Among subjects with blood 
type A, there was significant weight loss in the vegetarian-like diet group 
compared to the control diet group (p=0.037).  Among subjects with blood type 
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O, there was a trend for weight loss in the vegetarian-like diet group compared to 
the control diet group (p=0.092).  See Table 4 and Figure 9 below for details on 
weight loss values.   
Subjects in the vegetarian-like diet group also experienced a significant 
decrease in BMI compared to the control diet group (-0.2±0.4 and +0.1±0.3 
respectively; p<0.01).  The vegetarian-like dietary intervention had a large effect 
size for change in BMI (20.8%).  For those who followed the vegetarian-like diet,  
both blood types O and A experienced significant decreases in BMI compared to 
their counterparts in the control diet group (p=0.092 and p=0.037, respectively).  
Details on BMI are represented in Table 4 and Figure 10. 
Although the vegetarian-like diet group lost weight over the four week 
study, based on computations from the FFQs, the amount of kilocalories 
consumed per day did not change from week 0 to week 4. A two-way, between-
group ANOVA revealed that diet group effect on change in kilocalories did not 
reach significance (one outlier was removed).  However, change in weight was 
highly correlated to change in kilocalories (r=0.418/ p=0.008), although, when the 
same outlier was removed, significance was lost. 
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Table 4. Change in values for weight, BMI, and Kcals over four weeks in four study 
groups
a
 
 
Variable 
Control  
Type O 
(n=9) 
Control  
Type A 
(n=9) 
Experimental 
Type O 
(n=10) 
Experimental 
Type A 
(n=11) p Value
b
 
Weight
c
 (lb) 0.5±3.2 0.8±1.2 -1.8±2.6
+
 -0.9±2.1* 0.011 
BMI
c
 0.1±0.5 0.1±0.2 -0.3±0.4* -0.2±0.3* 0.005 
Kcal/day -143±451 -105±476 -221±426 -353±493 0.284 
      
 
aData presented as mean±SD 
bp value represents group effect analyzed by two-way, between-group ANOVA 
cOne outlier removed; *differs significantly from control; +trend of difference from control 
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Chapter 5 
DISCUSSION 
Clotting Variables 
 We originally hypothesized that there would be no difference in blood 
coagulation between type A and type O blood groups after adhering to a 
vegetarian-like diet for four weeks, given the lack of published research on blood 
type and diet.  Contrary to this hypothesis, there was a significant diet group 
effect for blood type O.  Type Os in the vegetarian-like diet group had an 
increased PT of +0.24±0.32 seconds (p=0.050).  However, type As in the 
vegetarian-like diet group saw relatively no change in PT.   
 A prolonged PT is typically evidential of a possible bleeding disorder, but 
a shortened PT may be associated with an increased risk of thrombosis.  A 
reduction in PT of 0.2 seconds may represent an important change in terms of risk 
for CVD.  Freedman et al. conducted a cross-sectional study of male US Army 
veterans in which they examined associations between PT and traits linked to 
CVD (81).  They found that mean PT was 0.2 seconds shorter among cigarette 
smokers compared to nonsmokers.  Cigarette smoking is an established risk factor 
for CVD.  The type Os in the vegetarian-like diet group saw a reduction in PT on 
par with nonsmokers versus smokers.  Freedman et al. also noted several other 
inverse associations between PT and CVD risk factors including weight, total 
cholesterol, and triglycerides. 
 APTT is another blood coagulation test often performed in conjunction 
with PT.  Whereas both tests measure the common coagulation pathway, APTT 
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specifically tests the intrinsic pathway.  When taken alongside a normal PT, 
APTT can point to a clotting factor deficiency in the intrinsic pathway.  The 
reverse situation, in which PT is prolonged and APTT is normal, indicates a 
deficiency in the extrinsic pathway.  When both test results are prolonged, it 
points to an inhibition or deficiency in the common coagulation pathway (refer 
back to Figure 4 in chapter 2) (82).  Change in PT and change in APTT over our 
four week trial had a medium positive correlation (r=0.331/ p=0.039). 
 Beyond using APTT as a test to indicate bleeding disorders, shorter APTT 
has been linked in research to risk for thrombotic disorders such as VTE.  In a 13 
year prospective study, Zakai et al. studied the relationship between baseline 
APTT and future incidence of VTE (83).  They found that baseline APTT values 
that fell below the median were associated with an increased risk of future VTE, 
even after adjusting for demographic and hemostatic factors.  When compared to 
subjects in the fourth quartile (with the longest APTTs), those in the first and 
second quartiles had a 2.4-fold and 1.9-fold higher risk for VTE.  The median 
value in Zakai’s study was 28.75 whereas in our study the median value for 
baseline APTT was 29.6 seconds.  Using Zakai’s median APTT of 28.75, 15 
subjects in our study fell below this value (9 of which were in the vegetarian-like 
diet group) and would be associated with an increased risk for VTE.  After the 
four week dietary intervention, one subject from the vegetarian-like diet group 
and one from the control diet group had an increased APTT time that was above 
28.75, suggesting the vegetarian-like diet did not make a difference on this 
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measure.  Indeed, we saw no significant change in this value when analyzed by a 
two-way, between-group ANOVA. 
 Interestingly, Zakai et al. also found an association between non-O blood 
groups and a lower APTT.  In the first quartile 85% were non-O blood types 
whereas only 60% were non-O in the fourth quartile.  Similarly, in our study, a 
one-way ANOVA performed on baseline APTT values using blood type as a 
factor revealed a trend for type As to have a shorter APTT (29.0±2.4 sec) than 
type Os (30.2±1.6 sec) (p=0.069). 
 It is not clear why we saw a significant increase in PT for type Os in the 
vegetarian-like diet group, but no significant increase in APTT.  Perhaps the diet 
affected some factor in the extrinsic clotting pathway for type Os, but not in the 
intrinsic or common pathways.  The possibility also exists that there was a 
preanalytical cause of inaccuracy.  For example, prolonged time lapses between 
collection and measurement by the lab may produce erroneous results (82).  
Finally, the significant finding may have been due to chance. 
 As for VWF, plasma concentration at week 0 was significantly higher in 
blood type A than blood type O.  This difference corresponds with previous 
research discussed in the literature review of this thesis.  VWF concentration did 
not change after our four week dietary intervention.  VWF and PT were not 
correlated in our study, but VWF and APTT shared a strong negative correlation 
(r=-0.595/ p<0.001).  This would be expected given VWF’s role in protecting 
FVIII, one of the clotting factors involved in the intrinsic pathway of coagulation.  
Actually, APTT is a commonly used test to help diagnose Von Willebrand 
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Disease (84).  Based on the link between higher VWF levels and increased risk 
for CVD, it is of interest to pursue further studies that look at dietary interventions 
that lower risk of thrombosis.  The addition of other hemostatic measures, such as 
platelet aggregation, would give a broader picture of how diet affects hemostasis. 
Lipids and CRP 
 There were no significant changes in the study subjects’ lipid profiles or 
CRP levels after the four week vegetarian-like dietary intervention.  However, the 
study subjects were healthy, young adults with lipid and CRP values that fell 
within normal ranges.  The average total cholesterol for all study subjects at week 
0 was 154.1±27.9 mg/dl, which is well below the “desirable” category of <200 
mg/dl recommended by the National Heart, Lung, and Blood Institute (NHLBI) 
(85).  Average HDL for all study subjects at week 0 was 62.4±16.3 mg/dl, which 
falls into the “best” category of HDL levels at >60 mg/dl, recommended by 
NHLBI.  Average LDL for all study subjects at week 0 was 88.3±25.0 mg/dl, 
which falls within the <100 mg/dl recommendation by NHLBI for people with 
risk of heart disease, and well below the recommendation of <130 mg/dl for 
healthy adults.  Average triglyceride level for all study subjects at week 0 was 
82.2±32.1 mg/dl, which falls well below the NHLBI recommendation of <150 
mg/dl.  Finally, average CRP for all study subjects at week 0 was 2.0±2.8 mg/L.  
When CRP is used as a biomarker for heart disease risk, 2.0 mg/L is classified as 
“medium” risk (low <1.0 mg/L; medium 1.0 to 3.0 mg/L; high >3.0 mg/L) (86).  
Being that the study subjects started with very healthy cholesterol, triglyceride, 
and CRP levels, the dietary intervention was not expected to have a large impact 
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on these measures.  If the study were to be repeated, picking subjects from a 
population with increased lipid and CRP levels, such as those at risk for heart 
disease, may better reveal how the vegetarian-like diet impacts these measures. 
Weight and BMI 
 Subjects who followed the vegetarian-like diet for four weeks lost nearly a 
pound and a half.  Based on calculations from FFQs, both blood types O and A in 
the vegetarian-like diet group reduced their caloric intake, however, because 
controls also reported a slight reduction in calories, the difference did not reach 
significance.  Beyond the fact that reduction in calories leads to weight loss, 
research by Canfi et al. suggests that alterations in consumption from specific 
food groups affects weight loss (87).  They observed that an increase in 
vegetables consumed and a decrease in cookies and cakes were universal weight 
loss predictors, regardless of diet type (low fat, low carbohydrate, or 
Mediterranean diet).  In our study, subjects in the vegetarian-like diet saw a trend 
towards an increase in fruit and vegetable consumption from 21±8 weekly 
servings at week 0 to 28±17 weekly servings at week 4 (p=0.086).  The control 
diet group saw no change in fruit and vegetable consumption at all.  Also, the 
vegetarian-like diet group significantly decreased their consumption of sweets 
from 7±6 weekly servings at week 0 to 2±3 weekly servings at week 4 (p=0.003), 
whereas the control diet group’s consumption of sweets remained the same.  See 
Figure 11 for further detail. 
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One of the main dietary changes those in the vegetarian-like diet group 
underwent was the elimination of red meat.  Research is inconsistent when it 
comes to the effect of red meat on weight and BMI.  Vergnaud et al. noted a 
significant positive association between red meat consumption (as well as total 
meat, poultry and processed meats) and weight gain in a five year prospective 
study of adults aged 25 to 70 years (88).  However, in a subsequent study by 
Gilsing et al., red meat consumption was not associated with changes in BMI over 
a 14 year follow-up of older adults aged 55 to 69 years (89).  Yet they did note 
significant associations between increased BMI and pork consumption in women 
and chicken consumption in both women and men.  In our study, the vegetarian-
like diet group significantly reduced their BMI by 0.2, suggesting that eliminating 
red meat may contribute to a reduction in BMI. 
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Limitations 
 Our study was powered for our primary outcome measures of PT and 
APTT, and therefore was underpowered to find significant change in caloric 
consumption.  In order to power for change in caloric intake at 80%, a total of 246 
subjects would have to be enrolled in this parallel-arm study.  Future studies 
should include more subjects.  Also, the dietary intervention in this study occurred 
outside of a controlled setting, and subjects were responsible for adhering to the 
dietary guidelines themselves.  Because their compliance and food intake was 
self-reported, the possibility of inaccuracies exists.     
The Evidence-Based Blood Type Diet 
The outcome of this study is contradictory to D’Adamo’s 
recommendations for blood type A.  It was not the type As, but the type Os who 
faired best on the vegetarian-like diet in our study.  Type Os saw an increase in 
PT indicating that their blood clotting times were lengthened, perhaps reducing 
the risk of thrombosis and its related health complications.  It seems that blood 
type A is less responsive to the dietary intervention and may require more rigid 
dietary guidelines or a longer time on such a diet to see the benefits.  While some 
of D’Adamo’s recommendations are backed by research, others are not. 
In order to overcome an increased risk of CVD linked to higher levels of 
VWF, blood type As should emphasize those foods that have been established as 
antithrombic and heart healthy by scientific research.  Referring back to the foods 
discussed in the literature review section, type As would likely benefit from the 
Mediterranean diet, emphasizing olive oil, fish (such as salmon), red wine, and 
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fruits and vegetables.  Type As should cook often with garlic, onion, and ginger.  
Tomatoes are also a large component of the Mediterranean diet that have been 
shown to inhibit platelet aggregation.  This is contrary to Dr. D’Adamo’s advice 
that type As should avoid tomatoes because they agglutinate blood cells.  When 
choosing carbohydrate-rich foods, type As should avoid those high on the 
glycemic index and focus on whole grain products.  Plant-based foods high in 
polyphenols are also very healthy for type As, such as black tea, apples, soy, dark 
chocolate, and red wine. 
Conclusion 
Results from this study suggest that a vegetarian-like diet may improve 
coagulation measures, especially in individuals with blood type O.  However, 
because blood type As are at an increased risk of CVD due to their higher levels 
of VWF, future studies are warranted to explore dietary interventions that can 
reduce risk in type As.  Further exploration is also needed into how PT and APTT 
relate to risk of CVD.  They may prove to be a useful screening measure in 
addition to LDL and triglycerides, among others. 
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APPENDIX B 
QUESTIONNAIRES AND HANDOUTS: 
MEDICAL HISTORY QUESTIONNAIRE 
FOOD FREQUENCY QUESTIONNAIRE 
TYPE A DIET GUIDELINES  
MEAL REPLACEMENT GUIDE 
COMPLIANCE CALENDAR 
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HEALTH / MEDICAL HISTORY QUESTIONNAIRE                                                       ID#___________________ 
 
1. (To be completed by researchers): Height _________  Weight __________ 
 
Percent body fat _________  BMI _________ 
 
2. Age:  __________     Gender:  ____________ 
 
3. Have you lost or gained more than 5 lbs in the last 12 months?         Yes         No 
 
      If yes, how much lost or gained? _________     How long ago? ___________ 
 
4. College Status (please circle)    Fresh.      Soph.     Jr.     Sr.     Grad.           Not Applicable 
 
5. Ethnicity: (please circle)  Native American     African-American     Caucasian     Hispanic     Asian     Other 
 
6. Do you smoke?           No, never ________   
 
                                  Yes           ________     # Cigarettes per day = ________        
                        
                                                 I used to, but I quit _______ months/years (circle) ago 
 
7.  Do you take any medications regularly?     Yes No           If yes, list type and frequency: 
     
Medication    Dosage     Frequency 
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
__________________________________________________________________________________________________ 
 
 
8. Do you currently take supplements (vitamins, minerals, herbs, etc.) ?    Yes    No         If yes, list type and frequency:                               
     
Supplement    Dosage     Frequency 
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________  
__________________________________________________________________________________________________
__________________________________________________________________________________________________
_________________________________________________________________________________________________ 
 
 
9.  Have you ever been hospitalized? ______ If yes, for what? _______________________________________ 
 
    OVER → 
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10.   Please ANSWER (YES/NO) if you currently have or if you have ever been diagnosed with any of the 
following diseases or symptoms: 
 
 YES NO  YES NO 
Coronary Heart Disease   Chest Pain   
High Blood Pressure   Shortness of Breath   
Heart Murmur   Heart Palpitations   
Rheumatic Fever   Any Heart Problems   
Irregular Heart Beat   Coughing of Blood   
Varicose Veins   Feeling Faint or Dizzy   
Stroke   Lung Disease   
Diabetes   Liver Disease   
Low Blood Sugar   Kidney Disease   
Bronchial Asthma   Thyroid Disease   
Hay Fever   Anemia   
Leg or Ankle Swelling   Hormone Imbalances   
Eating Disorders   Emotional Problems   
Hemophilia   Lupus   
Other bleeding disorder   Cancer   
Vitamin K deficiency      
 
Please elaborate on any condition listed above.___________________________________________________ 
_________________________________________________________________________________________ 
 
 
11.  How would you rate your lifestyle? 
Not active ___________       Active ___________ 
Somewhat active __________      Very Active ___________ 
 
12. Please circle the total time you spend in each category for an average week. 
  
Light activities such as: 
 Slow walking, golf, slow cycling, doubles tennis, easy swimming, gardening 
 Hours per week:     0  1  2  3  4  5  6  7  8  9  10+ 
  
Moderate activities such as: 
 Mod. Walking, mod. cycling, singles tennis, mod. swimming, mod. weight lifting 
 Hours per week:     0  1  2  3  4  5  6  7  8  9  10+ 
  
Vigorous activities such as: 
 Fast walking/jogging, fast cycling, court sports, fast swimming, heavy/intense 
 weight lifting 
                   Hours per week:     0  1  2  3  4  5  6  7  8  9  10+ 
 
13.  How much alcohol do you drink? (average # drinks per day)  ___________ 
 
14.  Do you have any food allergies?          Yes    No       If yes, explain:________________________________________ 
 
15. Do you follow a special diet? (weight gain/loss, vegetarian, low-fat, etc.)  Yes    No        
              
     If yes, explain:  __________________________________________________________________________________ 
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ID Number: __________________________    Date: _____________________ 
Food Frequency Questionnaire 
This questionnaire will give us information about your eating habits.  There are no “right” or “wrong” 
answers.  Accurate and thoughtful responses are appreciated! 
 Use the past month as your standard for how you eat. 
 Recall the times during the day when you ate, and what you had. 
 Include snacks as well as meals and beverages. 
 If you ate out regularly or traveled, remember to include those foods too. 
 Please answer every item on this form.  If you did not eat a food listed below, or ate it less than 
once a week, write a ‘0’ in the space provided.  Please do not leave blanks. 
For each of the foods listed below, please indicate how many servings per week you usually ate in the 
past month.  Where indicated, check whether your servings are large, small, or about average in size. 
Food Item 
Average 
Weekly 
Servings 
Serving Size: Size of 
average 
serving 
Small Average Large 
Red meat (beef, pork and ham, veal, 
lamb) 
 
 
_________ 
□ □ □ 4 ounces (size of deck of cards) 
Meat dishes (casseroles, tacos, pizza, 
meat sauce) 
 
 
_________ 
□ □ □ 1 cup casserole, 1 taco or pizza slice 
Chicken or turkey 
 
_________ □ □ □ 1 large or 2 small pieces 
Fish (such as salmon or tuna, including 
fish canned in water) 
 
_________ □ □ □ 4 ounces,  ½ can 
Shellfish (such as lobster, shrimp, 
clams, oysters, scallops, crab, and 
squid/calamari) 
 
_________ □ □ □ 4 ounces 
Bacon, sausage 
 
_________ □ □ □ 2 pieces 
Hot dogs 
 
_________ □ □ □ 1 hot dog 
Luncheon meats: salami, bologna, 
ham, roast beef 
 
_________ □ □ □ 1 piece 
Luncheon meats: chicken, turkey 
 
_________ □ □ □ 1 piece 
How many of the above servings are 
from fast food outlets (McDonald’s, 
Taco Bell, etc.)? 
 
_________     
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Food Item 
Average 
Weekly 
Servings 
Serving Size: Size of 
average 
serving 
Small Average Large 
Eggs (scrambled, hard boiled, over 
easy, etc.) 
 
_________ □ □ □ 1 egg 
Cow’s milk 
 
_________ □ □ □ 1 cup  (8 ounces) 
Yogurt (derived from cow’s milk) 
 
_________ □ □ □ 1 cup  (8 ounces) 
Cottage cheese 
 
_________ □ □ □ 1 cup  (8 ounces) 
Hard cheese (cheddar, Monterey jack, 
Swiss, provolone, etc.) 
 
_________ □ □ □ 1 ounce/slice 
Cream cheese 
 
_________ □ □ □ 1 ounce 
Ice cream 
 
_________ □ □ □ ½ cup  (1 scoop) 
Frozen yogurt 
 
_________ □ □ □ ½ cup  (1 scoop) 
Soy milk 
 
_________ □ □ □ 1 cup  (8 ounces) 
Soy yogurt 
 
_________ □ □ □ 1 cup  (8 ounces) 
Soy cheese 
 
_________ □ □ □ 1 ounce/slice 
Olive, flaxseed, or walnut oil 
 
_________ □ □ □ 1 tablespoon 
Coconut, corn, or peanut oil 
 
_________ □ □ □ 1 tablespoon 
Peanuts and peanut butter 
 
_________ □ □ □ 2 tablespoons 
Walnuts 
 
_________ □ □ □ 2 tablespoons 
Cashews 
 
_________ □ □ □ 2 tablespoons 
Pistachios 
 
_________ □ □ □ 2 tablespoons 
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Food Item 
Average 
Weekly 
Servings 
Serving Size: Size of 
average 
serving 
Small Average Large 
Black beans 
 
_________ □ □ □ ¾ cups (cooked) 
Pinto beans 
 
_________ □ □ □ ¾ cups (cooked) 
Lentils 
 
_________ □ □ □ ¾ cups (cooked) 
Garbanzo beans (chickpeas); including 
hummus 
 
_________ □ □ □ ¾ cups (cooked) 
Kidney beans 
 
_________ □ □ □ ¾ cups (cooked) 
Oatmeal 
 
_________ □ □ □ 1 medium bowl 
Shredded wheat cereal 
 
_________ □ □ □ 1 medium bowl 
Sprouted wheat bread (eg. Ezekiel) 
 
_________ □ □ □ 1 slice 
English muffin 
 
_________ □ □ □ 1 muffin 
Whole wheat bread 
 
_________ □ □ □ 1 slice 
White bread 
 
_________ □ □ □ 1 slice 
Pasta (from durum or semolina) 
 
_________ □ □ □ 1 cup 
Pasta (from whole wheat flour) 
 
_________ □ □ □ 1 cup 
Quinoa 
 
_________ □ □ □ ¾ cups (cooked) 
Rice (all varieties) 
 
_________ □ □ □ ¾ cups (cooked) 
Chips or French fries 
 
_________ □ □ □ 1 cup 
Nightshade vegetables (Potatoes, 
tomatoes, sweet and hot peppers, 
eggplant, tomatillos, tamarios, 
pepinos, and pimientos) 
 
_________ □ □ □ 1 cup raw or ½ cup cooked 
  85 
 
  
Food Item 
Average 
Weekly 
Servings 
Serving Size: Size of 
average 
serving 
Small Average Large 
All other vegetables (non-nightshades) 
 
_________ □ □ □ 1 cup raw or ½ cup cooked 
Berries (blackberries, blueberries, 
cranberries, etc.) 
 
_________ □ □ □ 1 cup raw 
Bananas 
 
_________ □ □ □ 1 medium banana 
Orange 
 
_________ □ □ □ 1 medium orange 
Grapefruit 
 
_________ □ □ □ 1 medium grapefruit 
All other fruit (not listed above) 
 
_________ □ □ □ 1 piece 
Mustard 
 
_________ □ □ □ 1 tablespoon 
Soy sauce 
 
_________ □ □ □ 1 tablespoon 
Mayonnaise 
 
_________ □ □ □ 1 tablespoon 
Ketchup 
 
_________ □ □ □ 1 tablespoon 
Salad dressing 
 
_________ □ □ □ 2 tablespoons 
Vinegar (balsamic and other varieties) 
 
_________ □ □ □ 1 tablespoon 
Baked desserts and pastries (cake, 
cookies, etc.) 
 
_________ □ □ □ 1 slice or 2 cookies 
Donuts or sweet rolls 
 
_________ □ □ □ 1 piece 
Chocolate or candy bars 
 
_________ □ □ □ 1 regular size candy bar 
Soda (including regular and diet) 
 
_________ □ □ □ 1 large glass/ 1 12 oz can 
Coffee 
 
_________ □ □ □ 1 cup/ 8 ounces 
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Food Item 
Average 
Weekly 
Servings 
Serving Size: Size of 
average 
serving 
Small Average Large 
Green tea 
 
_________ □ □ □ 1 cup/ 8 ounces 
Black tea 
 
_________ □ □ □ 1 cup/ 8 ounces 
Fruit juice 
 
_________ □ □ □ 1 cup/ 8 ounces 
Red wine 
 
_________ □ □ □ 6 ounces 
Beer 
 
_________ □ □ □ 12 ounces 
Liquor 
 
_________ □ □ □ 1.5 ounces 
 
 
    
 
Please look over this form to be sure you answered every question.  Do not leave any items blank. 
 
Thank you! 
 
 
 
 
 
 
 
 
 
 
 
This FFQ has been adopted from Kaiser Permanente’s FFQ available at 
http://www.permanente.net/homepage/kaiser/pdf/6116.pdf (accessed 1/24/2012). 
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Meal Replacement Guide 
Emphasize foods in their natural state and eat fresh as much as possible.  Avoid overly processed and 
refined foods. 
If you usually eat… Try instead! 
  
Breakfast  
 Bagel with cream cheese  Oatmeal with berries and walnuts 
 Shredded wheat cereal with cow’s milk  Corn flakes with soy milk 
 Egg McMuffin  Yogurt parfait with cherries 
 Half and half in coffee  Soy milk 
 Black tea  Green tea 
 Orange juice  Grapefruit juice 
  
Lunch  
 Hamburger  Veggie burger or chicken sandwich 
 French fries  Carrot sticks 
 Beef burrito  Pinto bean burrito (no cheese) 
 Potato chips  Apple slices 
 Ham sandwich  Tuna sandwich  
 Cobb salad  Greek salad 
 Soda  Cranberry juice 
  
Dinner  
 Spaghetti with tomato sauce  Pasta with basil pesto 
 Beef stew  Lentil soup 
 Pork chops  Baked, seasoned tofu 
 Mashed potatoes  Black beans and rice 
 Bread and butter  Mixed salad with oil & squeezed lemon 
 Pepperoni pizza  Vegetarian lasagna with pesto sauce 
 Bottle of beer  Glass of red wine 
 Ice cream  Frozen yogurt 
 Cheese cake  Reese’s peanut butter cups 
  
Snacks  
 Nachos  Rice cake with peanut butter 
 String cheese  Raw almonds 
 Beef jerky  Soy beans (edamame) 
 Hummus and crackers  Dried apricots 
  
Pain Relief  
 Aspirin, Advil, or Aleve   Tylenol 
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March 2012 
SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY 
    1 2 3 
       
4 5 6 7 8 9 10 
       
11 12 13 14 15 16 17 
       
18 19 20 21 22 23 24 
       
25 26 27 28 29 30 31 
       
 
April 2012 
SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY 
1 2 3 4 5 6 7 
       
8 9 10 11 12 13 14 
       
15 16 17 18 19 20 21 
       
22 23 24 25 26 27 28 
       
29 30      
       
 
INSTRUCTIONS 
For every day you have complied with the study diet, please place an ‘X’ in 
that date’s box.  For days on which you eat items that are not allowed, 
please make a note of the food (eg. “4 oz steak”).  Please do your best to 
keep an accurate record and report all deviations.  Thank you for your 
participation! 
 
Contact the researchers if you have any questions at:  
Dr. Carol Johnston: Carol.Johnston@asu.edu, 602-827-2265 
Jennifer Brown: Jennifer.M.Brown@asu.edu, 623-332-3335 
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APPENDIX D 
ANALYTICAL PROCEDURES 
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Procedure for EldonCard™ 2511-1 ABO-Rh Home Blood Typing Test Kit 
(Adopted from instruction manual included with kit.) 
Test principle: 
 The test is based on direct haemagglutination.  The antibody reagents on 
the card will agglutinate red blood cells with corresponding antigens.  No 
agglutination in a field indicates the absence of the corresponding antigen.  The 
blood group of the individual is determined from the agglutination pattern on the 
EldonCard. 
Reagents: 
 The anti-A field contains murine IgM monoclonal anti-A from cell line 
Birma-1 
 The anti-B field contains murine IgM monoclonal anti-B from cell line 
LB-2 
 The anti-D field contains human monoclonal IgM anti-D from cell line 
MS-201 
 The control field contains no antibodies but the same phosphate buffer as 
the other fields 
Additional materials required: 
 Either clean tap water, distilled water, isotonic saline or phosphate 
buffered saline 
 Lancet 
 EldonSticks, 4 per card 
Procedure for capillary blood: 
1. Fill in the data of the person being tested. 
2. With a pipette, apply 20 µl of water onto each of the circular fields. 
3. Disinfect the finger at the puncture site with a cleansing tissue.  Let the 
finger air dry. 
4. Puncture the skin by pushing the lancet firmly against the fingertip. 
5. Keep the arm down for about 10 seconds to stimulate the blood flow.  
Gently press the blood towards the fingertip.  Repeat pressing until a drop 
with a 3 to 4 mm (1/8 inch) diameter is seen.  Apply the blood onto an 
EldonStick, approached from beneath the finger.  Don’t smear the blood 
over the skin.  Place the stick onto the first circular field.  The blood shall 
touch the water applied in step 2. 
6. To develop all possible agglutinates the card must be tilted at least 40 
seconds.  Tilt the EldonCard to an almost upright position and wait 10 
seconds.  A wave of blood will move the red cells slowly to the bottom of 
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the fields.  Tilt to the opposite vertical position and wait another 10 
seconds while the blood flows down the fields.  Tilt twice more on the 
remaining edges for 10+10 seconds.  The results can now be read and 
recorded. 
7. The EldonCard may be disposed of at this point, or it can be left on a 
horizontal surface to dry.  When dry, it can be covered with a piece of 
ELDON FOIL 2511 and kept as a permanent record of the result.  
Results: 
Agglutination of the red cells in a field is considered a positive result and 
denoted “+” in the table below.  No agglutination is considered a negative result 
and denoted “-” in the table.  The possible reaction patterns on the card and 
corresponding blood groups: 
Reaction in Field Blood Group 
Anti-A Anti-B Anti-D Control ABO RhD 
- - + - O Pos 
- - - - O Neg 
+ - + - A Pos 
+ - - - A Neg 
- + + - B Pos 
- + - - B Neg 
+ + + - AB Pos 
+ + - - AB Neg 
+ + + + Invalid result 
 
If a positive reaction is observed in the Control field, the test result is 
invalid and the test has to be repeated. 
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Procedure for IMUBIND® vWF ELISA Kit 
(Adopted from instruction manual included with kit.) 
Intended use: 
The IMUBIND® vWF ELISA kit is an enzyme-linked immunoassay for 
the quantitation of vWF antigen in human plasma.  This assay is for research use 
only. It is not intended for diagnostic or therapeutic procedures. 
Principle of the procedure: 
The IMUBIND vWF ELISA is a "sandwich" ELISA using a goat 
polyclonal antibody as the capture antibody. Samples incubate in precoated 
micro-test wells and the same polyclonal antibody, horseradish peroxidase (HRP) 
conjugated, is used to detect the bound vWF antigen. The addition of 
perborate/3,3',5,5' - tetramethylbenzidine (TMB) substrate, and its subsequent 
reaction with the HRP, creates a blue colored solution. Sensitivity is enhanced by 
the addition of a 0.5M sulfuric acid stop solution, yielding a yellow colored 
solution. vWF levels are determined by measuring and comparing the absorbance 
of sample solutions at 450 nm against those of a standard curve developed using 
calibrated antigen. 
Reagents: 
 6 strips of 16 antibody coated microwells in holder and acetate cover sheet 
 6 vials vWF standards, 0 - 10 mU/mL (lyophilized) 
 1 vial Detection Antibody, HRP-conjugated anti-human vWF (135 μL) 
 1 vial Detection Antibody Diluent (lyophilized) 
 1 vial Substrate, TMB (11 mL) 
 1 packet Wash Buffer, PBS with 0.05% Tween 20, pH 7.4 
There are sufficient reagents to assay 42 plasma samples and generate a 6-
point standard curve (both tested in duplicate). Samples may be patient, control or 
reference plasmas. 
Reagent preparation and storage: 
1. Precoated Microwell Strips: Once removed from the foil pouch, the 
microwell strips should be used within 30 minutes. Unused strips may be 
stored at 2°-8°C for 4 weeks when sealed in the original pouch with the 
desiccant present, protected from any moisture. 
2. Standards:  Add 1.0 mL distilled H20 to the 0.5, 1.0, 2.0, 5.0 and 10.0 
mU/mL standard vials.  Add 2.0 mL distilled H20 to the 0 mU/mL 
standard vial.  Agitate gently.  Do not shake!  Reconstituted vWF 
standards are stable for up to 1 month when stored at –20°C or colder. 
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3. Detection Antibody:  Supplied as a concentrated solution. Detection 
Antibody is diluted to working strength immediately before adding to the 
microwells. Concentrated Detection Antibody is stable until the expiration 
date stated on the vial when stored at 2°-8°C. Unused working strength 
Detection Antibody should be discarded. 
4. Detection Antibody Diluent:  Add 20 mL of distilled H2O to the Detection 
Antibody Diluent vial.  Mix well.  Reconstituted Detection Antibody 
Diluent may be used for up to 1 month when stored at 2°-8°C. 
5. Substrate:  Supplied ready to use. Once opened, the substrate may be used 
for up to 1 month when stored at 2°-°C. 
6. Wash Buffer:  Dissolve the contents of the Wash Buffer packet in 900 mL 
distilled H2O.  QS. to a final volume of 1 Liter with distilled H2O.  Mix 
well and confirm pH is 7.4 (adjust if necessary).  Wash Buffer may be 
used for up to 1 month when stored at 2°-8°C. 
7. Sample Buffer:  Prepare an appropriate amount of Sample Buffer by 
adding BSA to Wash Buffer to a final concentration of 3% w/v (3 gm 
BSA/100 mL Wash Buffer). Sample Buffer may be used for up to 2 weeks 
when stored at 2°-8°C. 
Specimen collection and preparation: 
Either citrate or EDTA collected platelet poor plasma may be used for this 
assay. See "Collection, Transport and Preparation of Blood Specimens for 
Coagulation Testing and Performance of Coagulation Assays", NCCLS 
Document H21-A3, Vol. 18, No. 20, December 1998. Plasma collection should be 
performed as follows: 
1. Collect 9 parts of blood into 1 part of 3.2% (0.109 M) trisodium citrate 
anticoagulant solution. 
2. Centrifuge the blood sample at 1,500 x g for 15 minutes. 
3. Plasma should be stored at 2°-8°C and assayed within 4 hours. 
Alternatively, plasma may be stored at –20°C for up to 6 months. 
4. Frozen plasma should be thawed rapidly at 37°C. Thawed plasmas should 
be stored at 2°-8°C and assayed within 4 hours. 
5. Dilute plasma sample 1:100 in Sample Buffer. 
Procedure: 
1. Open the foil pouch and remove the microwell/frame assembly. Remove 
those microwell strips that will not be used and replace them in the foil 
pouch with the desiccant inside. Reseal the pouch and store at 2°-8°C. 
2. Add 100 ìL of vWF standard or diluted sample to a microwell, cover with 
the acetate sheet and incubate for 1 hour at room temperature. It is 
recommended to perform measurements in duplicate. 
3. Wash the microwells 4 times with wash buffer (250 ìL per well). 
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4. Prepare working strength Detection Antibody by diluting the concentrate 
1:100 as follows: add 20 ìL of Detection Antibody to 2 mL of Detection 
Antibody Diluent. Then add 100 ìL of working strength Detection 
Antibody to each microwell, cover with the acetate sheet and incubate for 
1 hour at room temperature. 
5. Wash the microwells 4 times with wash buffer (250 ìL per well). 
6. Add 100 ìL of Substrate to each microwell, cover with acetate sheet and 
incubate for 20 minutes at room temperature. A blue color will develop. 
7. Stop the enzymatic reaction by adding 50 ìL of 0.5M H2SO4. Tap the 
sides of the strip wells to ensure even distribution of the H2SO4. The 
solution color will turn yellow. Immediately read the absorbances of the 
solutions on a microwell plate reader set at a wavelength of 450 nm. 
Results: 
Construct a standard curve by plotting the mean absorbance value for each vWF 
Standard versus its corresponding concentration. A standard curve should be 
generated each time the assay is performed. The following standard curve is for 
demonstration purposes only. 
 
Calculation: 
Use the mean absorbance value for each diluted sample to interpolate its 
vWF concentration from the standard curve. Multiply the concentration 
determined from the standard curve by 100 (the dilution factor) to obtain the vWF 
concentration in the original plasma sample. 
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Procedure for Prothrombin time (PT) and  
activated partial thromboplastin time (APTT) 
The following information was adopted from www.medical.siemens.com. 
About the Sysmex® CA-7000 System: 
The Sysmex® CA-7000 System is a fully automated, high performance, 
cap-piercing analyzer that efficiently processes routine and specialty assays. 
Utilizing complete random-access capabilities and second generation cap-
piercing, it is the fastest throughput coagulation analyzer available for routine 
testing. 
PT reagents used: 
 Thromborel® S 
 Dade® Innovin 
APTT reagents used: 
 Dade Actin®  
 Dade Actin FS  
 Dade Actin FSL  
 Pathromtin™ SL 
The following information was adopted from www.sonoraquest.com. 
Prothrombin time: 
 Specimen Requirements:  1 refrigerated blue-top (sodium citrate) tube. 
Allow 2.7 mL blood to be drawn by vacuum. A completely filled blue-top 
tube is required. Do not centrifuge or freeze. Send unopened tube 
refrigerated. If testing is to be delayed beyond 48 hours, centrifuge tube 
and separate only top 2/3 of platelet-free plasma into a plastic vial and 
freeze immediately (1 mL minimum). Place in specimen bag with Frozen 
Specimen label applied and transport frozen. 
 Stability:  48 hours refrigerated or room temperature if tube has not been 
opened. 4 hours if tube has been opened. 1 month if submitted as frozen 
plasma. 
 Minimum Collection Volume:  1. 3.0 mL light blue top tube 2. 1.0 mL 
FROZEN citrated plasma 
 Methodology:  Photo Optical Clot Detection 
 Rejection Reason:  1. Specimen clotted 2. Effective: 5/1/00, specimens 
submitted with incorrect blood anticoagulant ratio will not be tested. 3. 
Age of specimen. 4. Gross hemolysis 5. Clotted 6. Plasma not frozen. 7. 
High hematocrit. 
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 Transport Temperature:  1. Blue top tube - Refrigerated 2. Plasma - Frozen 
 Container Type:  Blue top tube, 3.2% sodium citrate tube Frozen plasma 
Activated Partial Thromboplastin Time: 
 Specimen Requirements:  1 refrigerated blue-top (sodium citrate) tube. 
Allow 2.7 mL blood to be drawn by vacuum. A completely filled blue-top 
is required. Do not centrifuge or freeze. Send unopened tube refrigerated. 
If testing is to be delayed beyond 24 hours, immediately centrifuge tube 
and separate only top 2/3 of platelet-free plasma into a plastic vial and 
freeze immediately. Place in specimen bag with Frozen Specimen label 
and transport frozen. NOTE: For heparinized patients, always submit 
frozen plasma (1 mL minimum). 
 Stability:  1. 24 hrs - Blue top tube refrigerated or room temperature if 
tube has not been opened. 4 hours if tube has been opened. 2. 1 week 
frozen citrate plasma 
 Minimum Collection Volume:  1. 3 mL Blue Top Tube 2. 1.0 mL 
FROZEN citrated plasma 
 Methodology:  Photo-Optical Clot Detection 
 Rejection Reason:  1. Transported in a glass vial. 2. Specimen submitted 
with incorrect blood/anticoagulant ratio. 3. Age of specimen 4. Hemolysis 
5. Plasma not recd frozen. 6. Clotted 7. High hematocrit 
 Transport Temperature:  Blue top tube - Refrigerated Plasma - frozen 
 Container Type:  1. Blue top tube 2. Plastic aliquot tube- from 3.2% 
Sodium Citrate Tube. 
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Procedure for Total Cholesterol 
COBAS® C 111 
(Adopted from instruction manual included with test.) 
Intended use: 
In vitro test for the quantitative determination of cholesterol in human 
serum and plasma on the cobas c 111 system. 
Specimen collection and preparation: 
 For specimen collection and preparation, only use suitable tubes or 
collection containers.  Only the specimens listed below were tested and found 
acceptable. 
 Serum. 
 Plasma: Li-heparin, K3-EDTA plasma. (Use of EDTA plasma leads to 
slightly lower values). 
 Do not use citrate, oxalate, or fluoride. 
 Fasting and nonfasting samples can be used. 
 The sample types listed were tested with a selection of sample collection 
tubes that were commercially available at the time of testing, i.e. not all available 
tubes of all manufacturers were tested. Sample collection systems from various 
manufacturers may contain differing materials which could affect the test results 
in some cases. When processing samples in primary tubes (sample collection 
systems), follow the instructions of the tube manufacturer. Centrifuge samples 
containing precipitates before performing the assay. 
Stability: 7 days at 15-25 °C, 7 days at 2-8 °C, 3 months at (-15)-(-25) °C 
Assay: 
For optimum performance of the assay follow the directions given in this 
document for the analyzer concerned. Refer to the appropriate operator’s manual 
for analyzer-specific assay instructions. The performance of applications not 
validated by Roche is not warranted and must be defined by the user. 
Application for serum and plasma: 
cobas c 111 test definition: 
 Measuring mode = Absorbance 
 Abs. calculation mode = Endpoint 
 Reaction direction = Increase 
 Wavelength A/B = 512/659 nm 
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 Calc. first/last = 6/37 
 Unit = mmol/L 
 Reaction mode = R-S 
Pipetting parameters: 
 Diluent (H2O) 
 R 47 μL 70 μL 
 Sample 2 μL 23 μL 
 Total volume 142 μL 
Calculation: 
The cobas c 111 analyzer automatically calculates the analyte concentration of 
each sample. 
Conversion factors:  
 mmol/L x 38.66 = mg/dL 
 mmol/L x 0.3866 = g/L 
 mg/dL x 0.0259 = mmol/L 
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Procedure for LDL Cholesterol 
COBAS® C 111 
(Adopted from instruction manual included with test.) 
Intended use: 
In vitro test for the quantitative determination of LDL-cholesterol in 
human serum and plasma on the cobas c 111 system. 
Specimen collection and preparation: 
 For specimen collection and preparation, only use suitable tubes or 
collection containers. Only the specimens listed below were tested and found 
acceptable: 
 Serum. 
 Plasma: Li-heparin plasma. 
 EDTA plasma causes decreased values. 
 Fasting and non-fasting samples can be used.  The sample types listed 
were tested with a selection of sample collection tubes that were commercially 
available at the time of testing, i.e. not all available tubes of all manufacturers 
were tested. Sample collection systems from various manufacturers may contain 
differing materials which could affect the test results in some cases. When 
processing samples in primary tubes (sample collection systems), follow the 
instructions of the tube manufacturer. 
Centrifuge samples containing precipitate before performing the assay. 
Stability:12 7 days at 2-8 °C, 30 days at -70 °C 
Assay: 
For optimum performance of the assay follow the directions given in this 
document for the analyzer concerned. Refer to the appropriate operator’s manual 
for analyzer-specific assay instructions. The performance of applications not 
validated by Roche is not warranted and must be defined by the user. 
Application for serum and plasma: 
cobas c 111 test definition: 
 Measuring mode = Absorbance 
 Abs. calculation mode = Endpoint 
 Reaction direction = Increase 
 Wavelength A/B = 583/659 nm 
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 Calc. first/last = 16/37 
 Unit  = mmol/L 
 Reaction mode = R1-S-SR 
Pipetting parameters: 
 Diluent (H2O) 
 R1 150 μL 
 Sample 2 μL 7 μL 
 SR 50 μL 
 Total volume 209 μL 
Calculation: 
The cobas c 111 analyzer automatically calculates the analyte concentration of 
each sample. 
Conversion factors:  
 mmol/L x 38.66 = mg/dL 
 mmol/L x 0.3866 = g/L 
 mg/dL x 0.0259 = mmol/L 
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Procedure for HDL Cholesterol 
COBAS® C 111 
(Adopted from instruction manual included with test.) 
Intended use: 
In vitro diagnostic test for the quantitative determination of the HDL-
cholesterol concentration in human serum and plasma on the cobas c 111 system. 
Specimen collection and preparation: 
For specimen collection and preparation, only use suitable tubes or 
collection containers.  Only the specimens listed below were tested and found 
acceptable. 
Serum. 
 Plasma: Li-Heparin, K3-EDTA plasma. 
 EDTA plasma causes decreased results. 
Fasting and non-fasting samples can be used. Collect blood by using an 
evacuated tube or syringe. Specimens should preferably be analyzed on the day of 
collection. The sample types listed were tested with a selection of sample 
collection tubes that were commercially available at the time of testing, i.e. not all 
available tubes of all manufacturers were tested. Sample collection systems from 
various manufacturers may contain differing materials which could affect the test 
results in some cases. When processing samples in primary tubes (sample 
collection systems), follow the instructions of the tube manufacturer. Centrifuge 
samples containing precipitates before performing the assay. 
Stability:19 7 days at 2-8 °C 
30 days at -70 °C 
Assay: 
For optimum performance of the assay follow the directions given in this 
document for the analyzer concerned. Refer to the appropriate operator’s manual 
for analyzer-specific assay instructions. The performance of applications not 
validated by Roche is not warranted and must be defined by the user. 
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Application for serum and plasma: 
cobas c 111 test definition: 
 Measuring mode = Absorbance 
 Abs. calculation mode = Endpoint 
 Reaction direction = Increase 
 Wavelength A/B = 583/659 nm 
 Calc. first/last = 16/37 
 Unit mmol/L 
 Reaction mode = R1-S-SR 
Pipetting parameters: 
 Diluent (H2O) 
 R1 150 μL 
 Sample 2.5 μL 7.0 μL 
 SR 50 μL 
 Total volume 209.5 μL 
Calculation: 
The cobas c 111 analyzer automatically calculates the analyte concentration of 
each sample. 
Conversion factors:  
 mmol/L x 38.66 = mg/dL 
 mmol/L x 0.3866 = g/L 
 mg/dL x 0.0259 = mmol/L 
  
  106 
Procedure for Triglycerides 
COBAS® C 111 
(Adopted from instruction manual included with test.) 
Intended use: 
In vitro test for the quantitative determination of triglycerides in human 
serum and plasma on the cobas c 111 system. 
Specimen collection and preparation: 
For specimen collection and preparation, only use suitable tubes or collection 
containers. Only the specimens listed below were tested and found acceptable. 
 Serum 
 Plasma: Li-heparin, K3-EDTA plasma. 
 EDTA tubes that are less than 1/2 full may cause a negative bias for 
triglycerides results. 
Patients should refrain from eating for 10 to 14 hours before blood is drawn.  
Samples must be drawn in a soap and glycerol free collection device. The sample 
types listed were tested with a selection of sample collection tubes that were 
commercially available at the time of testing, i.e. not all available tubes of all 
manufacturers were tested. Sample collection systems from various manufacturers 
may contain differing materials which could affect the test results in some cases. 
When processing samples in primary tubes (sample collection systems), follow 
the instructions of the tube manufacturer. Centrifuge samples containing 
precipitates before performing the assay. 
Stability:7 5-7 days at 2-8 °C, 3 months at (-15)-(-25) °C, several years at (-60)-(-
80) °C 
Assay: 
For optimum performance of the assay follow the directions given in this 
document for the analyzer concerned. Refer to the appropriate operator’s manual 
for analyzer-specific assay instructions. The performance of applications not 
validated by Roche is not warranted and must be defined by the user. 
Application for serum and plasma: 
cobas c 111 test definition: 
 Measuring mode = Absorbance 
 Abs. calculation mode = Endpoint 
 Reaction direction = Increase 
  107 
 Wavelength A/B = 512/659 nm 
 Calc. first/last = 6/21 
 Unit = mmol/L 
 Reaction mode = R-S 
Pipetting parameters: 
 Diluent (H2O) 
 R 120 μL 
 Sample 2 μL 28 μL 
 Total volume 150 μL 
Calculation: 
The cobas c 111 analyzer automatically calculates the analyte concentration of 
each sample. 
Conversion factors:  
 mmol/L × 88.5 = mg/dL 
 mg/dL × 0.0113 = mmol/L 
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Procedure for Triglycerides 
COBAS® C 111 
(Adopted from instruction manual included with test.) 
Intended use: 
In vitro test for the quantitative determination of C-reactive protein (CRP) 
in human serum and plasma on the cobas c 111 system. Measurement of CRP is 
of use for the detection and evaluation of inflammatory disorders and associated 
diseases, infection and tissue injury. Highly sensitive measurement of CRP may 
also be used as an aid in the assessment of the risk of future coronary heart 
disease. When used as an adjunct to other laboratory evaluation methods of acute 
coronary syndromes, it may also be an additional independent indicator of 
recurrent event prognosis in patients with stable coronary disease or acute 
coronary syndrome. 
Specimen collection and preparation: 
 For specimen collection and preparation, only use suitable tubes or 
collection containers. Only the specimens listed below were tested and found 
acceptable. 
 Serum 
 Plasma: Li-heparin, K2-EDTA plasma 
 The sample types listed were tested with a selection of sample collection 
tubes that were commercially available at the time of testing, i.e. not all available 
tubes of all manufacturers were tested. Sample collection systems from various 
manufacturers may contain differing materials which could affect the test results 
in some cases. When processing samples in primary tubes (sample collection 
systems), follow the instructions of the tube manufacturer. Centrifuge samples 
containing precipitates before performing the assay. 
Stability:24 11 days at 15-25 °C, 2 months at 2-8 °C, 3 years at (-15)-(-25) °C 
Assay: 
For optimum performance of the assay follow the directions given in this 
document for the analyzer concerned. Refer to the appropriate operator’s manual 
for analyzer-specific assay instructions. The performance of applications not 
validated by Roche is not warranted and must be defined by the user.  
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Application for serum and plasma:  
cobas c 111 test definition: 
 Measuring mode = Absorbance 
 Abs. calculation mode = Kinetic 
 Reaction direction = Increase 
 Wavelength A = 552 nm 
 Calc. first/last = 17/34 
 Unit = mg/L (nmol/L, mg/dL) 
 Reaction mode = R1-S-SR 
Pipetting parameters: 
 Diluent (H2O) 
 R1 82 μL 
 Sample 6 μL 48 μL 
 SR 28 μL 14 μL 
 Total volume 178 μL 
Calculation: 
The cobas c 111 analyzer automatically calculates the analyte concentration of 
each sample. 
Conversion factors:  
 mg/L x 9.52 = nmol/L 
 mg/L x 0.1 = mg/dL 
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DATA SUMMARY  
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Mean±SD in Four Study Groups at Week 0 and Week 4  
 
Control Type O 
(n=9) 
Control Type A 
(n=9) 
Experimental Type O 
(n=10) 
Experimental Type A 
(n=11) 
 
 
 
Week 0 Week 4 Week 0 Week 4 Week 0 Week 4 Week 0 Week 4 
Normal 
Rangea 
Weight (lb) 
162.2 
±42.5 
162.7 
±41.9 
138.2 
±14.7 
139.0 
±15.4 
145.7 
±20.8 
143.9 
±21.1+ 
150.1 
±29.1 
142.9 
±20.9* NA 
BMI 
25.0 
±5.3 
25.1 
±5.4 
23.3 
±2.7 
23.4 
±2.7 
23.3 
±3.3 
23.0 
±3.3* 
24.3 
±3.3 
23.6 
±2.7* 18.5-25.0 
PT (sec) 
10.8 
±0.9 
10.8 
±1.0 
10.7 
±0.3 
10.6 
±0.4 
10.7 
±0.3 
10.9 
±0.4* 
10.9 
±0.6 
10.9 
±0.6 9.0-11.5 
APTT (sec) 
30.1 
±1.3 
29.9 
±1.5 
28.8 
±2.3 
29.6 
±1.7 
30.3 
±2.0 
30.8 
±2.0 
29.1 
±2.7 
29.5 
±2.5 22.0-34.0 
VWF (mU/ml) 
627.7 
±152.6 
888.5 
±186.8 
991.3 
±374.1 
1076.6 
±247.6 
746.8 
±209.3 
895.1 
±377.3 
1029.1 
±237.9 
1288.0 
±153.6 varies 
Total Chol  
(mg/dl) 
165.6 
±40.6 
161.7 
±35.4 
152.6 
±29.3 
149.9 
±31.3 
146.8 
±22.0 
146.1 
±29.1 
152.7 
±18.6 
139.6 
±18.0 
<200 
mg/dl 
HDL (mg/dl) 
53.9 
±21.4 
48.7 
±17.2 
69.8 
±16.0 
69.2 
±12.7 
65.6 
±12.2 
67.7 
±14.0 
60.5 
±13.1 
57.0 
±12.1 >60 mg/dl 
LDL (mg/dl) 
105.8 
±32.6 
104.7 
±32.6 
81.6 
±24.1 
78.7 
±26.4 
77.1 
±19.3 
76.8 
±29.3 
89.8 
±16.6 
81.0 
±11.7 
<130 
mg/dl 
TG (mg/dl) 
104.5 
±35.2 
102.7 
±36.4 
69.7 
±27.0 
78.6 
±41.7 
78.9 
±35.4 
76.0 
±30.4 
77.1 
±24.1 
74.3 
±26.6 
<150 
mg/dl 
hsCRP (mg/L) 
3.95 
±4.28 
2.98 
±2.90 
0.94 
±0.86 
0.96 
±1.52 
1.94 
±2.84 
1.35 
±2.75 
1.47 
±1.51 
1.76 
±2.11 1.0-3.0 
Kcal/day 
1734 
±615 
1591 
±435 
1678 
±480 
1574 
±651 
1581 
±539 
1360 
±583 
1509 
±431 
1156 
±504 2000 
          
 
+p<0.10; *p<0.05.  See Results section for further detail. 
aSee discussion section for references for normal ranges. 
 
